09/690,353

Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:SSSPTA1208DXJ
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

| | | |
|---|---|---|
| NEWS 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS 2 | Dec 17 | The CA Lexicon available in the CAPLUS and CA files |
| NEWS 3 | Feb 06 | Engineering Information Encompass files have new names |
| NEWS 4 | Feb 16 | TOXLINE no longer being updated |
| NEWS 5 | Apr 23 | Search Derwent WPINDEX by chemical structure |
| NEWS 6 | Apr 23 | PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA |
| NEWS 7 | May 07 | DGENE Reload |
| NEWS 8 | Jun 20 | Published patent applications (A1) are now in USPATFULL |
| NEWS 9 | JUL 13 | New SDI alert frequency now available in Derwent's DWPI and DPCI |
| NEWS 10 | Aug 23 | In-process records and more frequent updates now in MEDLINE |
| NEWS 11 | Aug 23 | PAGE IMAGES FOR 1947-1966 RECORDS IN CAPLUS AND CA |
| NEWS 12 | Aug 23 | Adis Newsletters (ADISNEWS) now available on STN |
| NEWS 13 | Sep 17 | IMSworld Pharmaceutical Company Directory name change to PHARMASEARCH |
| NEWS 14 | Oct 09 | Korean abstracts now included in Derwent World Patents Index |
| NEWS 15 | Oct 09 | Number of Derwent World Patents Index updates increased |
| NEWS 16 | Oct 15 | Calculated properties now in the REGISTRY/ZREGISTRY File |
| NEWS 17 | Oct 22 | Over 1 million reactions added to CASREACT |
| NEWS 18 | Oct 22 | DGENE GETSIM has been improved |
| NEWS 19 | Oct 29 | AAASD no longer available |

| | |
|---|---|
| NEWS EXPRESS | August 15 CURRENT WINDOWS VERSION IS V6.0c, CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP), AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001 |
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability |
| NEWS INTER | General Internet Information |
| NEWS LOGIN | Welcome Banner and News Items |
| NEWS PHONE | Direct Dial and Telecommunication Network Access to STN |
| NEWS WWW | CAS World Wide Web Site (general information) |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:29:35 ON 02 NOV 2001

=> fil reg
COST IN U.S. DOLLARS

| | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.30 | 0.30 |

09/690,353

```
FILE 'REGISTRY' ENTERED AT 14:30:55 ON 02 NOV 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:     1 NOV 2001  HIGHEST RN 366444-38-4
DICTIONARY FILE UPDATES:    1 NOV 2001  HIGHEST RN 366444-38-4

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER see
HELP CROSSOVER for details.

Calculated physical property data is now available.  See HELP PROPERTIES
for more information.  See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> e cobalamin?
E1            2     COBALACTONE/BI
E2          343     COBALAMIN/BI
E3            0 --> COBALAMIN?/BI
E4           21     COBALAMINE/BI
E5            1     COBALAMINELACTAM/BI
E6            1     COBALAMINMONO/BI
E7            1     COBALAMINMONOCARBOXYL/BI
E8            1     COBALAMINMONOCARBOXYLIC/BI
E9            2     COBALAMINSULFONIC/BI
E10           1     COBALAMINTRI/BI
E11           1     COBALAMINTRICARBOXYL/BI
E12           1     COBALAMINTRICARBOXYLIC/BI

=> s e2
L1          343 COBALAMIN/BI

=> d
```

L1 ANSWER 1 OF 343 REGISTRY COPYRIGHT 2001 ACS
RN 357492-04-7 REGISTRY
CN **269Aa long cobalamin biosynthesis protein cobD (Sulfolobus tokodaii strain 7 gene ST2342) (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN GenBank AP000989-derived protein GI 15623463
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

09/690,353

```
=> fil .search
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         5.61       5.91

FILE 'MEDLINE' ENTERED AT 14:31:28 ON 02 NOV 2001

FILE 'CAPLUS' ENTERED AT 14:31:28 ON 02 NOV 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 14:31:28 ON 02 NOV 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'USPATFULL' ENTERED AT 14:31:28 ON 02 NOV 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 14:31:28 ON 02 NOV 2001
COPYRIGHT (C) 2001 Elsevier Science B.V.  All rights reserved.

=> s l1
L2       50399 L1

<------User Break------>
u
SEARCH ENDED BY USER

=> s l2 and (peptide? or polypeptide? or amino(w)acid?)
   2 FILES SEARCHED...
   4 FILES SEARCHED...
L3        3794 L2 AND (PEPTIDE? OR POLYPEPTIDE? OR AMINO(W) ACID?)

=> s l3 and (radionuclide? or radiolabel? or radioactiv? or radioisotop?)
L4         208 L3 AND (RADIONUCLIDE? OR RADIOLABEL? OR RADIOACTIV? OR RADIOISO
               TOP?)

=> s l4 and (chelat? or ligand?)
L5          72 L4 AND (CHELAT? OR LIGAND?)

=> dup rem l5
PROCESSING COMPLETED FOR L5
L6          68 DUP REM L5 (4 DUPLICATES REMOVED)

=> d ibib ab 1-
YOU HAVE REQUESTED DATA FROM 68 ANSWERS - CONTINUE? Y/(N):y
```

L6 ANSWER 1 OF 68 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2001:300552 CAPLUS
DOCUMENT NUMBER: 134:323118
TITLE: Cobalamin conjugates useful as tumor imaging and therapeutic agents
INVENTOR(S): Hogenkamp, Henricus P. C.; Collins, Douglas A.
PATENT ASSIGNEE(S): Mayo Foundation for Medical Education and Research, USA; Regents of the University of Minnesota
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001028595 | A1 | 20010426 | WO 2000-US10098 | 20000415 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-159753 A2 19991015
OTHER SOURCE(S): MARPAT 134:323118
AB The invention provides detectably labeled cobalamin derivs. which are useful for medical treatment and diagnosis. Cobalamin conjugates have **peptidas** or **amino acids** linked to metal **radionuclide chelates** or nonmetallic **radionuclides**.
REFERENCE COUNT: 4
REFERENCE(S):
(1) Biotech Australia Pty Ltd; WO 9427613 A 1994 CAPLUS
(2) Collins, D; US 5739313 A 1998 CAPLUS
(3) Collins, D; WO 0062808 A 2000 CAPLUS
(4) Grissom, C; WO 9808859 A 1998 CAPLUS

L6 ANSWER 2 OF 68 USPATFULL
ACCESSION NUMBER: 2001:163361 USPATFULL
TITLE: Discrete-length polyethylene glycols
INVENTOR(S): Wilbur, D. Scott, Edmonds, WA, United States
Pathare, Pradip M., Seattle, WA, United States
PATENT ASSIGNEE(S): The University of Washington, Seattle, WA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 6294697 | B1 | 20010925 |
| APPLICATION INFO.: | US 1998-62286 | | 19980417 (9) |
| RELATED APPLN. INFO.: | Continuation of Ser. No. WO 1996-US16760, filed on 18 Oct 1996 | | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 1995-5599 | 19951019 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Padmanabhan, Sreeni
LEGAL REPRESENTATIVE: Christensen O'Connor Johnson & Kindness PLLC
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 1072
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides discrete-length polyethylene glycol and polyethylene glycol containing compounds and methods for their preparation.

L6 ANSWER 3 OF 68 USPATFULL
ACCESSION NUMBER: 2001:152712 USPATFULL
TITLE: nrdG
INVENTOR(S): Black, Michael Terence, Chester Springs, PA, United States
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 6287804 | B1 | 20010911 |
| APPLICATION INFO.: | US 1998-40213 | | 19980317 (9) |

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Martinell, James
LEGAL REPRESENTATIVE: Gimmi, Edward R., Deibert, Thomas S., King, William T.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
LINE COUNT: 2108
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides nrdG **polypeptides** and polynucleotides encoding nrdG **polypeptides** and methods for producing such **polypeptides** by recombinant techniques. Also provided are methods for utilizing nrdG **polypeptides** to screen for antibacterial compounds.

L6 ANSWER 4 OF 68 USPATFULL
ACCESSION NUMBER: 2001:131279 USPATFULL
TITLE: Compositions of cobalamin and related corrinoids, and uses thereof
INVENTOR(S): Sarill, William J., 78 Hibbert St., Arlington, MA, United States 02154
Brennan, Thomas F., 44 A Gail Dr., Nyack, NY, United States 10960

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 6274564 | B1 | 20010814 |
| APPLICATION INFO.: | US 1997-936781 | | 19970917 (8) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 1996-25298 | 19960918 (60) |
| | US 1997-41750 | 19970328 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Travers, Russell
LEGAL REPRESENTATIVE: Lahive & Cockfield, LLP
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 1907
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel compositions cobalamin and related corrinoids, and uses thereof, are disclosed. The novel compositions include a corrin, a first **amino acid** having a side chain which includes a basic or positively charged moiety; and a second **amino acid** with an uncharged side chain which includes at least one heteroatom. The compositions are useful for, inter alia, treatment of cobalamin deficiency.

L6 ANSWER 5 OF 68 USPATFULL
ACCESSION NUMBER: 2001:98064 USPATFULL
TITLE: Ribb
INVENTOR(S): Black, Michael Terance, Chester Springs, PA, United States
Shilling, Lisa Kathleen, Newtown, PA, United States
Stodola, Robert King, Flourtown, PA, United States
Warren, Richard Lloyd, Blue Bell, PA, United States
Kosmatka, Anna Lisa, Doylestown, PA, United States
Nicholas, Richard Oakley, Collegeville, PA, United States
Palmer, Leslie Marie, Audubon, PA, United States
Lonetto, Michael Arthur, Collegeville, PA, United States
Fedon, Jason Craig, Strafford, PA, United States
Hodgson, John Edward, Malvern, PA, United States
Knowles, David Justin Charles, Boroughbridge, United Kingdom
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
SmithKline Beecham plc, United Kingdom (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 6252044 | B1 | 20010626 |
| APPLICATION INFO.: | US 1997-977555 | | 19971125 (8) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 1996-24022 | 19960816 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Minnifield, Nita
LEGAL REPRESENTATIVE: Gimmi, Edward R., Diebert, Thomas S., King, William T.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 1599
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides ribB **polypeptides** and polynucleotides encoding ribB **polypeptides** and methods for producing such **polypeptides** by recombinant techniques. Also provided are methods for utilizing ribB **polypeptides** to screen for antibacterial compounds.

L6 ANSWER 6 OF 68 USPATFULL
ACCESSION NUMBER: 2001:97419 USPATFULL
TITLE: Method and a system for enhanced in vivo clearance of diagnostic and/or therapeutic agents by extracorporeal depletion, and the use of said agents for said purpose
INVENTOR(S): Nilsson, Rune, Lund, Sweden
Lindgren, Lars, Lund, Sweden
Norrgren, Kristina, .ANG.karp, Sweden
Sandberg, Bengt, Lund, Sweden
Sjogren, Hans Olof, Lund, Sweden
Strand, Sven-Erik, Lund, Sweden
PATENT ASSIGNEE(S): Mitra Medical Technology AB, Lund, Sweden (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 6251394 | B1 | 20010626 |
| | WO 9212730 | | 19920806 |
| APPLICATION INFO.: | US 1993-90047 | | 19931012 (8) |
| | WO 1992-SE20 | | 19920115 |
| | | | 19931012 PCT 371 date |
| | | | 19931012 PCT 102(e) date |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | SE 1991-142 | 19910117 |

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Witz, Jean C.
LEGAL REPRESENTATIVE: Swanson & Bratschun L
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 656
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method and a system is described for reducing non-target levels of specific molecules intended for diagnostic and/or therapeutic applications to vertebrate hosts, wherein said molecules are administered to a vertebrate host and kept therein for a certain time in order to be concentrate to the target by being attached thereto. The molecules which are not attached to the target are removed from the blood circulation system or at least reduced to a lower concentration by passing the blood through an extra-corporeal device.

L6 ANSWER 7 OF 68 USPATFULL
ACCESSION NUMBER: 2001:17971 USPATFULL
TITLE: Transcobalamin mediated transport of vitamins B12 in intrinsic factor or receptor deficient patient
INVENTOR(S): Seetharam, Bellur, Brookfield, WI, United States
Bose, Santanu, San Francisco, CA, United States
PATENT ASSIGNEE(S): MCW Research Foundation, Milwaukee, WI, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 6183723 | B1 | 20010206 |
| APPLICATION INFO.: | US 1998-9995 | | 19980121 (9) |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Saucier, Sandra E.
ASSISTANT EXAMINER: Afremova, Vera
LEGAL REPRESENTATIVE: Quarles & Brady LLP
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 969
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for oral treatment of patients using different types of drugs that are not usually transported to circulation, if administered orally, is disclosed. Because the TC II-Cbl complex is stable to acid and proteolytic enzymes both outside and inside the intestinal absorptive cells, the method consists of oral administration of a drug bound to TC II-Cbl complex. In addition, the method can also be used for delivering Cbl to a large number of patients who do not absorb Cbl due to a variety of causes such as surgery of their stomach (ulcers) or of their terminal ileum (Crohn's disease).

L6 ANSWER 8 OF 68 USPATFULL
ACCESSION NUMBER: 2001:4509 USPATFULL
TITLE: ribH
INVENTOR(S): Black, Michael Terence, Chester Springs, PA, United States
Fedon, Jason Craig, Strafford, PA, United States
Hodgson, John Edward, Malvern, PA, United States
Knowles, David Justin Charles, Boroughbridge, United Kingdom
Lonetto, Michael Arthur, Collegeville, PA, United States
Kosmatka, Anna Lisa, Doylestown, PA, United States
Nicholas, Richard Oakley, Collegeville, PA, United States
Palmer, Leslie Marie, Audubon, PA, United States
Shilling, Lisa Kathleen, Newtown, PA, United States
Stodola, Robert King, Flourtown, PA, United States
Warren, Richard Lloyd, Blue Bell, PA, United States
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
SmithKline Beecham plc, United Kingdom (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 6171835 | B1 | 20010109 |
| APPLICATION INFO.: | US 1999-385288 | | 19990830 (9) |
| RELATED APPLN. INFO.: | Division of Ser. No. US 1997-978454, filed on 25 Nov 1997, now patented, Pat. No. US 6017728 Continuation of Ser. No. US 1997-911503, filed on 15 Aug 1997 Continuation of Ser. No. WO 1997-US14436, filed on 15 Aug 1997 | | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 1996-24022 | 19960816 (60) |

DOCUMENT TYPE: Patent
FILE SEGMENT: Granted
PRIMARY EXAMINER: Carlson, Karen Cochrane
LEGAL REPRESENTATIVE: Gimmi, Edward R., Deibert, Thomas S., King, William T.
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
LINE COUNT: 1355
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides ribH **polypeptides** and polynucleotides encoding ribH **polypeptides** and methods for producing such **polypeptides** by recombinant techniques. Also provided are methods for utilizing ribH **polypeptides** to screen for antibacterial compounds.

L6 ANSWER 9 OF 68 USPATFULL
ACCESSION NUMBER: 2000:157392 USPATFULL
TITLE: Vitamin B.sub.12 derivatives and methods for their preparation
INVENTOR(S): Russell-Jones, Gregory J., New South Wales, Australia
McEwan, John F., New South Wales, Australia
PATENT ASSIGNEE(S): Biotch Australia Pty Limited, Roseville, Australia (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 6150341 | | 20001121 |
| APPLICATION INFO.: | US 1999-330167 | | 19990611 (9) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | AU 1998-4050 | 19980612 |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wilson, James O.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 760
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to methods for preparing vitamin B.sub.12 (VB.sub.12) derivatives suitable for linking to a polymer, nanoparticle or therapeutic agent, protein or **peptide**. The methods involve reacting the 5'OH group of VB.sub.12 or an analogue thereof with an active carbonyl electrophile and subsequently obtaining said VB.sub.12 derivatives. The invention also relates to novel VB.sub.12 derivatives, VB.sub.12 derivatives prepared by the methods of the present invention and uses thereof in the preparation of in the preparation of polymer complexes or nanoparticles.

L6 ANSWER 10 OF 68 USPATFULL
ACCESSION NUMBER: 2000:125190 USPATFULL
TITLE: pcrA protein from Streptococcus pneumoniae
INVENTOR(S): Black, Michael Terence, Chester Springs, PA, United States
Hodgson, John Edward, Malvern, PA, United States
Knowles, David Justin Charles, Redhill, United Kingdom
Lonetto, Michael Arthur, Collegeville, PA, United States
Nicholas, Richard O, Collegeville, PA, United States
Stodola, Robert King, Flourtown, PA, United States
Holmes, David J, West Chester, PA, United States
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 6121414 | | 20000919 |
| APPLICATION INFO.: | US 1998-185825 | | 19981104 (9) |
| RELATED APPLN. INFO.: | Division of Ser. No. US 1997-889711, filed on 8 Jul 1997, now patented, Pat. No. US 5858718 | | |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Duffy, Patricia A.
LEGAL REPRESENTATIVE: Gimmi, Edward R., Deibert, Thomas S., King, William T.
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 1638
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides pcrA **polypeptides** and DNA (RNA) encoding pcrA **polypeptides** and methods for producing such **polypeptides** by recombinant techniques. Also provided are methods for utilizing pcrA **polypeptides** to screen for antibacterial compounds.

L6 ANSWER 11 OF 68 USPATFULL
ACCESSION NUMBER: 2000:84267 USPATFULL
TITLE: Water soluble vitamin B.sub.12 receptor modulating agents and methods related thereto
INVENTOR(S): Morgan, Jr., A. Charles, Mill Creek, WA, United States
Wilbur, D. Scott, Edmonds, WA, United States
Pathare, Pradip M., Seattle, WA, United States
PATENT ASSIGNEE(S): The University of Washington, Seattle, WA, United States (U.S. corporation)
Receptagen Corporation, Edmonds, WA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 6083926 | | 20000704 |
| APPLICATION INFO.: | US 1998-200422 | | 19981123 (9) |
| RELATED APPLN. INFO.: | Division of Ser. No. US 1995-545151, filed on 19 Oct 1995, now patented, Pat. No. US 5840712 which is a continuation-in-part of Ser. No. WO 1995-US4404, filed on 7 Apr 1995 which is a continuation-in-part of Ser. No. US 1995-406191, filed on 16 Mar 1995, now patented, Pat. No. US 5840880 which is a continuation-in-part of Ser. No. US 1995-406192, filed on 16 Mar 1995, now patented, Pat. No. US 5739287 And a continuation-in-part of Ser. No. US 1995-406194, filed on 16 Mar 1995, now patented, Pat. No. US 5869465 which is a continuation-in-part of Ser. No. US 1994-224831, filed on 8 Apr 1994, now abandoned | | |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fonda, Kathleen K.
LEGAL REPRESENTATIVE: Seed Intellectual Property Law Group PLLC
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 28 Drawing Figure(s); 18 Drawing Page(s)
LINE COUNT: 3274
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Vitamin B.sub.12 receptor modulating agents capable of modulating cell surface receptors by affecting the cell surface receptor trafficking pathway are disclosed. The vitamin B.sub.12 receptor modulating agents are comprised of a covalently bound rerouting moiety and targeting moiety linked by a water-solublizing linker.

L6 ANSWER 12 OF 68 USPATFULL
ACCESSION NUMBER: 2000:80599 USPATFULL
TITLE: Nucleophilic polysubstituted aryl acridinium ester conjugates and syntheses thereof
INVENTOR(S): Law, Say-Jong, Westwood, MA, United States
PATENT ASSIGNEE(S): Bayer Corporation, East Walpole, MA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 6080591 | | 20000627 |
| APPLICATION INFO.: | US 1997-920372 | | 19970829 (8) |
| RELATED APPLN. INFO.: | Continuation of Ser. No. US 1993-32947, filed on 17 Mar 1993, now patented, Pat. No. US 5663074 which is a continuation of Ser. No. US 1992-871601, filed on 17 Apr 1992, now patented, Pat. No. US 5241070 which is a continuation of Ser. No. US 1988-249620, filed on 26 Sep 1988, now abandoned | | |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wortman, Donna
ASSISTANT EXAMINER: Brumback, Brenda G.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 1138
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to novel nucleophilic polysubstituted aryl acridinium conjugates and the methods for preparation thereof. The novel nucleophilic polysubstituted aryl acridinium conjugates are useful in biological assays, including novel assays for the determination of Vitamin B.sub.12, folate, cortisol, estradiol, and thromboxane B.sub.2.

L6 ANSWER 13 OF 68 USPATFULL
ACCESSION NUMBER: 2000:18261 USPATFULL
TITLE: Glucose kinase from Streptococcus pneumoniae
INVENTOR(S): Black, Michael Terence, Chester Springs, PA, United States
Hodgson, John Edward, Malvern, PA, United States
Knowles, David Justin Charles, Redhill, United Kingdom
Lonetto, Michael Arthur, Collegeville, PA, United States
Nicholas, Richard O, Collegeville, PA, United States
Stodola, Robert King, Flourtown, PA, United States
Burnham, Martin Karl Russel, Norristown, PA, United States
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 6025175 | | 20000215 |
| APPLICATION INFO.: | US 1998-110910 | | 19980706 (9) |

RELATED APPLN. INFO.: Division of Ser. No. US 1997-896083, filed on 17 Jul 1997, now patented, Pat. No. US 5840560
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hobbs, Lisa J.
LEGAL REPRESENTATIVE: Gimmi, Edward R., King, William T., Deibert, Thomas S.
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 1521
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides Glucose Kinase **polypeptides** and DNA (RNA) encoding Glucose Kinase **polypeptides** and methods for producing such **polypeptides** by recombinant techniques. Also provided are methods for utilizing Glucose Kinase **polypeptides** to screen for antibacterial compounds.

L6 ANSWER 14 OF 68 USPATFULL
ACCESSION NUMBER: 2000:9717 USPATFULL
TITLE: ribH
INVENTOR(S): Black, Michael Terence, Chester Springs, PA, United States
Fedon, Jason Craig, Strafford, PA, United States
Hodgson, John Edward, Malvern, PA, United States
Knowles, David Justin Charles, Boroughbridge, United Kingdom
Kosmatka, Anna Lisa, Doylestown, PA, United States
Nicholas, Richard Oakley, Collegeville, PA, United States
Palmer, Leslie Marie, Audubon, PA, United States
Shilling, Lisa Kathleen, Newtown, PA, United States
Stodola, Robert King, Flourtown, PA, United States
Warren, Richard Lloyd, Blue Bell, PA, United States
Lonetto, Michael Arthur, Collegeville, PA, United States
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
SmithKline Beecham plc, United Kingdom (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 6017728 | | 20000125 |
| APPLICATION INFO.: | US 1997-978454 | | 19971125 (8) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 1996-24022 | 19960816 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Carlson, Karen Cochrane
LEGAL REPRESENTATIVE: Gimmi, Edward R., King, William T., Deibert, Thomas S.
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 1624
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides ribH **polypeptides** and polynucleotides encoding ribH **polypeptides** and methods for producing such **polypeptides** by recombinant techniques. Also provided are methods for utilizing ribH **polypeptides** to screen for antibacterial compounds.

L6 ANSWER 15 OF 68 MEDLINE DUPLICATE 1
ACCESSION NUMBER: 2000442250 MEDLINE
DOCUMENT NUMBER: 20443608 PubMed ID: 10990201
TITLE: Oral absorption of **peptides** through the cobalamin (vitamin B12) pathway in the rat intestine.
AUTHOR: Alsenz J; Russell-Jones G J; Westwood S; Levet-Trafit B; de
Smidt P C
CORPORATE SOURCE: Preclinical Research Department, F. Hoffman-La Roche Ltd., Basle, Switzerland.. jochem.alsenz@roche.com
SOURCE: PHARMACEUTICAL RESEARCH, (2000 Jul) 17 (7) 825-32.
Journal code: PHS. ISSN: 0724-8741.
PUB. COUNTRY: United States
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200101
ENTRY DATE: Entered STN: 20010322
Last Updated on STN: 20010322
Entered Medline: 20010118
AB PURPOSE: This study was aimed at examining the extent and mechanism of uptake of cobalamin (Cbl)-conjugated **peptides** in vitro and in vivo. METHODS: To enable acquisition of quantitative absorption data of Cbl-**peptides**, metabolically stable octapeptides (DP3), with (Cbl-Hex-DP3) or without a hexyl spacer (Cbl-DP3), were coupled to Cbl and **radiolabeled**. For comparison, LHRH coupled to Cbl was used as metabolically susceptible **peptide**. Biological recognition of Cbl-**peptides** was studied in the physiological order: binding by Intrinsic Factor (IF), recognition and transport of the IF-complexes by IF-Cbl receptors (IFCR) on Caco-2 monolayers and oral absorption of the Cbl-conjugates in the rat. RESULTS: All Cbl-**peptides** bound to IF and the IF-complexes were recognized by IFCR receptors on Caco-2 monolayers. Binding was saturable and could be inhibited by a 20-fold excess of IF-Cbl, but not of Non-intrinsic Factor (NIF)-Cbl. Oral administration of these **ligands** to rats resulted in absorption of 53%, 45%, 42%, and 23% of the applied **radioactivity** for Cbl, Cbl-LHRH, Cbl-Hex-DP3, and Cbl-DP3, respectively. Simultaneous administration of a >10(5)-fold excess of unlabeled Cbl reduced uptake of all compounds to <4%. Tissue distribution and elimination of the metabolically stable Cbl-conjugates were comparable to Cbl. CONCLUSIONS: The endogenous Cbl uptake pathway can be exploited for oral **peptide** delivery as indicated by the specific and high (40-45%) uptake of metabolically stable Cbl-coupled octapeptides.

L6 ANSWER 16 OF 68 USPATFULL
ACCESSION NUMBER: 1999:170440 USPATFULL
TITLE: Cell culturing method and medium
INVENTOR(S): Curcio, Francesco, Pagnacco, Italy
Coon, Hayden G., East Sebago, ME, United States
Ambesi-Impiombato, F. Saverio, Udine, Italy
PATENT ASSIGNEE(S): Livercell L.L.C., East Sebago, ME, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 6008047 | | 19991228 |
| APPLICATION INFO.: | US 1998-66897 | | 19980428 (9) |

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-480022, filed on 7 Jun 1993, now patented, Pat. No. US 5888816 which is a continuation of Ser. No. US 1993-83772, filed on 30 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-44010, filed on 8 Apr 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lankford, Jr., Leon B.
ASSISTANT EXAMINER: Tate, Christopher R.
LEGAL REPRESENTATIVE: Bundock Jr., John P.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 2290
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a method for producing an expanded non-transformed cell culture of human liver cells comprising the steps of: (1) preparing partially purified, minced human liver tissue, (2) concentrating the resulting cells and tissue pieces, (3) resuspending the concentrated tissue cells and pieces in a growth medium, (4) culturing the resuspended cells in the growth medium for a time and under conditions to effect sustained cell division, and (5) passaging the cultured human liver cells periodically to expand the culture. The growth medium comprises a combination of a basal medium and ingredients to provide a medium in which the cultured human liver cells are selectively proliferated without being transformed, providing an expanded culture of proliferated, functionally differentiated human liver cells that is substantially free of fibroblast, macrophage and capillary endothelial cells. Also provided is the improvement of harvesting cells of the expanded culture at a selected PDL preferably>5, providing a high density cell suspension of such proliferated human liver cells, and incubating such high density cell suspension in a calm-down medium to induce a mitotically quiescent state and, using a culture procedure which encourages aggregation, making the cells adhere tightly to form a three-dimensional cell organization typical of the organ of origin, thereby forming organoids.

L6 ANSWER 17 OF 68 USPATFULL
ACCESSION NUMBER: 1999:163707 USPATFULL
TITLE: Clioquinol for the treatment of Alzheimer's disease
INVENTOR(S): Gerolymatos, Panayotis N., Kryoneri Attikis, Greece
PATENT ASSIGNEE(S): P.N. Gerolymatos S.A., Kryoneri Attikis, Greece (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 6001852 | | 19991214 |
| APPLICATION INFO.: | US 1998-23544 | | 19980213 (9) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. WO 1997-IB983, filed on 8 Aug 1997 | | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | GR 1996-960100286 | 19960813 |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Criares, Theodore J.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1170
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A new pharmaceutical composition is disclosed that comprises clioquinol, vitamin B.sub.12, and, optionally, pharmaceutical acceptable carriers and/or excipients. The use of the pharmaceutical composition removes or alleviates the side effects of clioquinol.

L6 ANSWER 18 OF 68 USPATFULL
ACCESSION NUMBER: 1999:155706 USPATFULL
TITLE: Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
INVENTOR(S): Gerolymatos, Panayotis N., Kryoneri Attikis, Greece
PATENT ASSIGNEE(S): P.N. Gerolymatos S.A., Kryoneri Attikis, Greece (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 5994323 | | 19991130 |
| APPLICATION INFO.: | US 1998-23542 | | 19980213 (9) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | GR 1997-970100507 | 19971231 |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Criares, Theodore J.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1039
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A pharmaceutical composition is disclosed that comprises clioquinol, vitamin B.sub.12, and, optionally, pharmaceutical acceptable carriers and/or excipients. The use of the pharmaceutical composition removes or alleviates the side effects of clioquinol.

L6 ANSWER 19 OF 68 USPATFULL
ACCESSION NUMBER: 1999:155699 USPATFULL
TITLE: Method of preparing polynucleotide-carrier complexes for delivery to cells
INVENTOR(S): Lollo, Charles P., Encinitas, CA, United States
Mockler, Todd C., Carlsbad, CA, United States
Kwoh, Deborah Y., Carlsbad, CA, United States
PATENT ASSIGNEE(S): The Immune Response Corporation, Carlsbad, CA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 5994316 | | 19991130 |
| APPLICATION INFO.: | US 1996-604306 | | 19960221 (8) |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Campbell, Bruce R.
LEGAL REPRESENTATIVE: Lahive & Cockfield, LLP, Remillard, Jane E.
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 1587
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An improved method of forming substantially disperse and homogeneous polynucleotide-carrier complexes is disclosed. The polynucleotide-carrier complexes can be administered in vivo to obtain significant levels and duration of gene expression.

L6 ANSWER 20 OF 68 USPATFULL
ACCESSION NUMBER: 1999:89277 USPATFULL
TITLE: ribA
INVENTOR(S): Black, Michael Terence, Chester Springs, PA, United States
Fedon, Jason Craig, Strafford, PA, United States
Hodgson, John Edward, Malvern, PA, United States
Knowles, David Justin Charles, Boroughbridge, United Kingdom
Lonetto, Michael Arthur, Collegeville, PA, United States
Kosmatka, Anna Lisa, Doylestown, PA, United States
Nicholas, Richard Oakley, Collegeville, PA, United States
Palmer, Leslie Marie, Audubon, PA, United States
Shilling, Lisa Kathleen, Newtown, PA, United States
Stodola, Robert King, Flourtown, PA, United States
Warren, Richard Lloyd, Blue Bell, PA, United States
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
SmithKline Beecham p.l.c., United Kingdom (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 5932701 | | 19990803 |
| APPLICATION INFO.: | US 1997-978458 | | 19971125 (8) |
| RELATED APPLN. INFO.: | Continuation of Ser. No. WO 1997-US14436, filed on 15 Aug 1997 which is a continuation of Ser. No. US 1997-911503, filed on 15 Aug 1997 | | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 1996-24022 | 19960816 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Minnifield, Nita
LEGAL REPRESENTATIVE: King, William T., Gimmi, Edward R., Jackson, Arthur E.
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
LINE COUNT: 1726
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides ribA **polypeptides** and polynucleotides encoding ribA **polypeptides** and methods for producing such **polypeptides** by recombinant techniques. Also provided are methods for utilizing ribA **polypeptides** to screen for antibacterial compounds.

L6 ANSWER 21 OF 68 USPATFULL
ACCESSION NUMBER: 1999:40236 USPATFULL
TITLE: Cell cultures of and cell culturing method for nontransformed pancreatic, thyroid, and parathyroid cells
INVENTOR(S): Coon, Hayden G., Gaithersburg, MD, United States
Ambesi-Impiombato, Francesco Saverio, Tricesimo, Italy
Curcio, Francesco, Pagnacco, Italy
PATENT ASSIGNEE(S): Human Cell Cultures Inc., East Sebago, ME, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 5888816 | | 19990330 |
| APPLICATION INFO.: | US 1995-480022 | | 19950607 (8) |

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-83772, filed on 30 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-44010, filed on 8 Apr 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lankford, Jr., Leon B.
ASSISTANT EXAMINER: Tate, Christopher R.
LEGAL REPRESENTATIVE: Bundock, John P.
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 1992
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for producing an expanded, enriched, non-transformed human cell culture of human pancreatic, thyroid or parathyroid endocrine cells and other types of cells which comprises (1) preparing partially purified, minced tissue that includes a desired type of cells; (2) concentrating the desired cells; (3) resuspending the concentrated cells in a growth medium which selects in favor of the desired cells and in which those cells are proliferated without being transformed and differentiated functions are retained through periodic passaging; (4) culturing the resuspended cells in the growth medium to effect sustained cell division; and (5) passaging the cultured cells periodically to expand the culture. The present invention further provides clonal strains of cells derived from the above-mentioned cell culture and procedures to form matrix-embedded aggregated and non-aggregated cells for providing pseudotissues and products such as matrix-embedded pancreatic islets (pseudoislets). Growth medium and conditioned medium is provided for the culturing of the cells and clonal strains, the growth medium comprising a suitable basal medium supplemented with effective concentrations of hypothalamus and pituitary extracts, serum and other ingredients, which growth medium selects in favor of desired human cells and against passenger cells including fibroblast, macrophage, and capillary endothelial cells such that the desired cells are selectively proliferated without being transformed and an expanded cell culture is provided of functionally differentiated, expanded, non-transformed human cells that is substantially free of such passenger cells.

L6 ANSWER 21 OF 68 USPATFULL (Continued)

L6 ANSWER 22 OF 68 USPATFULL
ACCESSION NUMBER: 1999:36962 USPATFULL
TITLE: Methods for the detection of nitric oxide in fluid media
INVENTOR(S): Lai, Ching-San, Encinitas, CA, United States
PATENT ASSIGNEE(S): Medinox, Inc., San Diego, CA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 5885842 | | 19990323 |
| APPLICATION INFO.: | US 1996-745678 | | 19961108 (8) |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Green, Lora M.
ASSISTANT EXAMINER: Ricigliano, Joseph W.
LEGAL REPRESENTATIVE: Gray Cary Ware & Freidenrich, Reiter, Stephen E.
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 907
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Non-invasive methods have been developed for the measurement of NO levels in a variety of fluid media, e.g., body fluids. The present invention embraces the use of a semi-permeable vessel wherein said vessel contains an NO reacting substance to trap NO diffusing thereinto, and a simple physical or chemical detection method to measure the levels of the end products. Since NO is a neutral gas molecule, it is capable of diffusing freely across a wide range of biocompatible polymer membranes which exhibit a high permeability to NO and other neutral gas molecules, such as O.sub.2 and CO.sub.2, but which are not permeable to charged molecules, such as NO.sub.3.sup.- or NO.sub.2.sup.-. The latter two compounds are ubiquitously present in body fluids and often interfere with the measurement of NO levels. The permeability of selected membranes to NO, but not to NO.sub.3.sup.- or NO.sub.2.sup.-, makes it possible for the bags employed in the practice of the invention to selectively collect NO, even in the presence of potentially competing species. The simple, easy and non-invasive methods of the invention will find a variety of uses, e.g., for diagnosis and monitoring of NO overproduction (and underproduction) that has been associated with many inflammatory and infectious diseases.

L6 ANSWER 23 OF 68 USPATFULL
ACCESSION NUMBER: 1999:19129 USPATFULL
TITLE: Methods of receptor modulation and uses therefor
INVENTOR(S): Morgan, Jr., A. Charles, Edmonds, WA, United States
Wilbur, D. Scott, Edmonds, WA, United States
PATENT ASSIGNEE(S): Receptagen Corporation, Edmonds, WA, United States (U.S. corporation)
University of Washington, Seattle, WA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 5869465 | | 19990209 |
| APPLICATION INFO.: | US 1995-406194 | | 19950316 (8) |

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-224831, filed on 8 Apr 1994, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tsang, Cecilia J.
ASSISTANT EXAMINER: Gupta, Anish
LEGAL REPRESENTATIVE: Christensen O'Connor Johnson & Kindness PLLC
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 28 Drawing Figure(s); 18 Drawing Page(s)
LINE COUNT: 2882
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Receptor modulating agents capable of modulating cell surface receptors by affecting the cell surface receptor trafficking pathway are utilized for the treatment and diagnosis of a variety of disorders in warm-blooded animals, including neoplastic disorders. The receptor modulating agents are comprised of a covalently bound rerouting moiety and targeting moiety.

L6 ANSWER 24 OF 68 USPATFULL

ACCESSION NUMBER: 1999:4383 USPATFULL
TITLE: PCR A
INVENTOR(S): Black, Michael Terence, Chester Springs, PA, United States
Hodgson, John Edward, Malvern, PA, United States
Knowles, David Justin Charles, Redhill, United Kingdom
Lonetto, Michael Arthur, Collegeville, PA, United States
O Nicholas, Richard, Collegeville, PA, United States
Stodola, Robert King, Flourtown, PA, United States
Holmes, David J., West Chester, PA, United States
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 5858718 | | 19990112 | |
| APPLICATION INFO.: | US 1997-889711 | | 19970708 | (8) |
| DOCUMENT TYPE: | Utility | | | |
| FILE SEGMENT: | Granted | | | |
| PRIMARY EXAMINER: | Duffy, Patricia | | | |
| LEGAL REPRESENTATIVE: | Gimmi, Edward R., King, William T., Jackson, Arthur E. | | | |
| NUMBER OF CLAIMS: | 11 | | | |
| EXEMPLARY CLAIM: | 1 | | | |
| LINE COUNT: | 1352 | | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides pcrA **polypeptides** and DNA (RNA) encoding pcrA **polypeptides** and methods for producing such **polypeptides** by recombinant techniques. Also provided are methods for utilizing pcrA **polypeptides** to screen for antibacterial compounds.

L6 ANSWER 25 OF 68 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 2

ACCESSION NUMBER: 1998:207280 CAPLUS
DOCUMENT NUMBER: 128:275101
TITLE: Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
INVENTOR(S): Unger, Evan C.; Matsunaga, Terry O.; Yellowhair, David
PATENT ASSIGNEE(S): Imarx Pharmaceutical Corp., USA
SOURCE: U.S., 40 pp. Cont.-in-part of U.S. Ser. No. 307,305.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 19
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 5733572 | A | 19980331 | US 1994-346426 | 19941129 |
| US 5088499 | A | 19920218 | US 1990-569828 | 19900820 |
| WO 9109629 | A1 | 19910711 | WO 1990-US7500 | 19901219 |
| W: CA, JP | | | | |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE | | | | |
| JP 05502675 | T2 | 19930513 | JP 1991-503276 | 19901219 |
| AT 180170 | E | 19990615 | AT 1991-902857 | 19901219 |
| ES 2131051 | T3 | 19990716 | ES 1991-902857 | 19901219 |
| US 5228446 | A | 19930720 | US 1991-717084 | 19910618 |
| WO 9222247 | A1 | 19921223 | WO 1992-US2615 | 19920331 |
| W: AU, CA, JP | | | | |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE | | | | |
| AU 9220020 | A1 | 19930112 | AU 1992-20020 | 19920331 |
| AU 667471 | B2 | 19960328 | | |
| JP 06508364 | T2 | 19940922 | JP 1992-500847 | 19920331 |
| EP 616508 | A1 | 19940928 | EP 1992-912456 | 19920331 |
| EP 616508 | B1 | 20010718 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE | | | | |
| AT 203148 | E | 20010815 | AT 1992-912456 | 19920331 |
| US 5469854 | A | 19951128 | US 1993-76239 | 19930611 |
| US 5580575 | A | 19961203 | US 1993-76250 | 19930611 |
| US 5348016 | A | 19940920 | US 1993-88268 | 19930707 |
| US 5542935 | A | 19960806 | US 1993-160232 | 19931130 |
| US 5585112 | A | 19961217 | US 1993-159687 | 19931130 |
| US 5769080 | A | 19980623 | US 1994-199462 | 19940222 |
| WO 9428874 | A1 | 19941222 | WO 1994-US5633 | 19940519 |
| W: AU, CA, CN, JP | | | | |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| US 5773024 | A | 19980630 | US 1994-307305 | 19940916 |
| CA 2177713 | AA | 19950608 | CA 1994-2177713 | 19941130 |
| JP 09506098 | T2 | 19970617 | JP 1994-515763 | 19941130 |
| US 5571497 | A | 19961105 | US 1995-468056 | 19950606 |
| CN 1180310 | A | 19980429 | CN 1996-193069 | 19960327 |
| US 6001335 | A | 19991214 | US 1996-665719 | 19960618 |
| US 5935553 | A | 19990810 | US 1996-758179 | 19961125 |
| US 5985246 | A | 19991116 | US 1997-888426 | 19970708 |
| AU 713127 | B2 | 19991125 | AU 1998-56271 | 19980224 |
| AU 9856271 | A1 | 19980507 | | |
| AU 9888405 | A1 | 19981203 | AU 1998-88405 | 19981012 |
| AU 731072 | B2 | 20010322 | | |

L6 ANSWER 25 OF 68 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 2
(Continued)

| | | | | |
|---|---|---|---|---|
| AU 9910043 | A1 | 19990304 | AU 1999-10043 | 19990104 |
| PRIORITY APPLN. INFO.: | | | US 1989-455707 B2 | 19891222 |
| | | | US 1990-569828 A2 | 19900820 |
| | | | US 1991-716899 B2 | 19910618 |
| | | | US 1991-717084 A2 | 19910618 |
| | | | US 1993-76239 A2 | 19930611 |
| | | | US 1993-76250 A2 | 19930611 |
| | | | US 1993-159674 B2 | 19931130 |
| | | | US 1993-159687 A2 | 19931130 |
| | | | US 1993-160232 A2 | 19931130 |
| | | | US 1994-307305 A2 | 19940916 |
| | | | WO 1990-US7500 W | 19901219 |
| | | | US 1991-750877 A3 | 19910826 |
| | | | US 1992-818069 A3 | 19920108 |
| | | | WO 1992-US2615 A | 19920331 |
| | | | US 1992-967974 A3 | 19921027 |
| | | | US 1993-17683 A3 | 19930212 |
| | | | US 1993-18112 B3 | 19930217 |
| | | | US 1993-85608 A3 | 19930630 |
| | | | US 1993-88268 A3 | 19930707 |
| | | | US 1993-309305 A | 19931130 |
| | | | US 1993-163039 A3 | 19931206 |
| | | | US 1994-212553 B2 | 19940311 |
| | | | AU 1994-70416 A3 | 19940519 |
| | | | US 1994-346426 | 19941129 |
| | | | AU 1995-21850 A3 | 19941130 |
| | | | WO 1994-US13817 W | 19941130 |
| | | | US 1995-395683 A3 | 19950228 |
| | | | US 1995-468056 A3 | 19950606 |
| | | | US 1995-471250 A3 | 19950606 |
| | | | US 1996-665719 A3 | 19960618 |

AB Gas and gaseous precursor filled microspheres, and foams provide novel topical and s.c. delivery vehicles for various active ingredients, including drugs and cosmetics. Gas and gaseous precursor filled microcapsules were prepd. from dipalmitoylphosphatidylcholine.

L6 ANSWER 26 OF 68 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1998:55494 CAPLUS
DOCUMENT NUMBER: 128:112664
TITLE: Pressure-mediated binding of biomolecular complexes
INVENTOR(S): Litt, Gerald J.; Laugharn, James A., Jr.; Green, David J.; Hess, Robert A.; Paulus, Henry
PATENT ASSIGNEE(S): Bioseq, Inc., USA; Litt, Gerald J.; Laugharn, James A., Jr.; Green, David J.; Hess, Robert A.; Paulus, Henry
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9800032 | A1 | 19980108 | WO 1997-US11198 | 19970701 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| CA 2259318 | AA | 19980108 | CA 1997-2259318 | 19970701 |
| AU 9736437 | A1 | 19980121 | AU 1997-36437 | 19970701 |
| EP 924991 | A1 | 19990630 | EP 1997-933189 | 19970701 |
| EP 924991 | B1 | 20011004 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| US 1996-20562 | P | 19960702 |
| US 1997-44595 | P | 19970422 |
| WO 1997-US11198 | W | 19970701 |

AB The invention relates to (1) pressure-mediated dissocn. of an analyte complexed with an endogenous binding partner to enable detection of a complex formed from the analyte and an exogenous binding factor, (2) pressure-mediated assocn. of an analyte and an exogenous binding partner to enable more rapid and/or more sensitive detection of an analyte, and (3) pressure-mediated assocn. and dissocn. of biomol. complexes to enable sepn. of one biomol. from a complex mixt. Pressure can be used to improve assays by dissocg. endogenous analyte complexes and improving assay speed and sensitivity by assocg. the analyte mols. with exogenously supplied binding partners. Pressure can also be used to improve the sepn. of compds. from contaminated mixts.

L6 ANSWER 27 OF 68 USPATFULL
ACCESSION NUMBER: 1998:157191 USPATFULL
TITLE: Cell cultures of and cells culturing method for nontransformed parotid cells
INVENTOR(S): Coon, Hayden G., Gaithersburg, MD, United States
Ambesi-Impiombato, Francesco Saverio, Tricesimo, Italy
Curcio, Francesco, Pagnacco, Italy
PATENT ASSIGNEE(S): Human Cell Cultures Inc., East Sebago, ME, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 5849584 | | 19981215 |
| APPLICATION INFO.: | US 1995-485650 | | 19950607 (8) |
| RELATED APPLN. INFO.: | Continuation of Ser. No. US 1993-83772, filed on 30 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-44010, filed on 8 Apr 1993, now abandoned | | |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Lankford, Jr., Leon B. | | |
| ASSISTANT EXAMINER: | Tate, Christopher R. | | |
| LEGAL REPRESENTATIVE: | Bundock, John P. | | |
| NUMBER OF CLAIMS: | 17 | | |
| EXEMPLARY CLAIM: | 1 | | |
| NUMBER OF DRAWINGS: | 18 Drawing Figure(s); 11 Drawing Page(s) | | |
| LINE COUNT: | 1832 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for producing an expanded non-transformed cell culture comprising the steps of: (1) preparing partially purified, minced tissue; (2) concentrating the resulting cells and tissue pieces; (3) resuspending the concentrated tissue cells and pieces in a culture medium capable of supporting sustained cell division that is contained in a culture vessel; (4) incubating the cells; and (5) passaging the cells periodically. The present invention further provides clonal strains of cells derived from the above-mentioned cell culture, medium and conditioned medium designed for the culturing of parotid cells and other glandular cells such as pancreatic, thyroid, and parathyroid, and cells, and the use of cultured pancreatic cells to form pancreatic pseudotissues composed of matrix-embedded aggregated (pseudoislets) or individual cells, to treat blood sugar disorders in mammals, and to test for cytotoxicity and autoimmune activities with reference to pancreatic endocrine cells. The nontransformed cells are cultured in a growth medium comprising a suitable basal medium supplemented with effective concentrations of hypothalamus and pituitary extracts, and serum.

L6 ANSWER 28 OF 68 USPATFULL
ACCESSION NUMBER: 1998:147590 USPATFULL
TITLE: Receptor modulating agents
INVENTOR(S): Morgan, Jr., A. Charles, Edmonds, WA, United States
Wilbur, D. Scott, Edmonds, WA, United States
PATENT ASSIGNEE(S): Receptagen Corporation, Edmonds, WA, United States (U.S. corporation)
University of Washington, Seattle, WA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 5840880 | | 19981124 |
| APPLICATION INFO.: | US 1995-406191 | | 19950316 (8) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 1994-224831, filed on 8 Apr 1994, now abandoned | | |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Robinson, Douglas | | |
| ASSISTANT EXAMINER: | Gupta, Anish | | |
| LEGAL REPRESENTATIVE: | Christensen O'Connor Johnson & Kindness PLLC | | |
| NUMBER OF CLAIMS: | 13 | | |
| EXEMPLARY CLAIM: | 1 | | |
| NUMBER OF DRAWINGS: | 26 Drawing Figure(s); 20 Drawing Page(s) | | |
| LINE COUNT: | 2940 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Receptor modulating agents capable of modulating cell surface receptors by affecting the cell surface receptor trafficking pathway. The receptor modulating agents are comprised of a covalently bound rerouting moiety and targeting moiety.

L6 ANSWER 29 OF 68 USPATFULL
ACCESSION NUMBER: 1998:147427 USPATFULL
TITLE: Water soluble vitamin B.sub.12 receptor modulating agents and methods related thereto
INVENTOR(S): Morgan, Jr., A. Charles, Mill Creek, WA, United States
Wilbur, D. Scott, Edmonds, WA, United States
Pathare, Pradip M., Seattle, WA, United States
PATENT ASSIGNEE(S): Receptagen Corporation, Edmonds, WA, United States (U.S. corporation)
University of WA, Edmonds, WA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 5840712 | | 19981124 |
| APPLICATION INFO.: | US 1995-545151 | | 19951019 (8) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 1995-406191, filed on 16 Mar 1995 Ser. No. Ser. No. US 1995-406192, filed on 16 Mar 1995, now patented, Pat. No. US 5739287 And Ser. No. US 1995-406194, filed on 16 Mar 1995 , each Ser. No. US which is a continuation-in-part of Ser. No. US 1994-224831, filed on 8 Apr 1994, now abandoned | | |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Hutzell, Paula K. | | |
| ASSISTANT EXAMINER: | Bakalyar, Heather A. | | |
| LEGAL REPRESENTATIVE: | Christensen O'Connor Johnson & Kindness PLLC | | |
| NUMBER OF CLAIMS: | 10 | | |
| EXEMPLARY CLAIM: | 1 | | |
| NUMBER OF DRAWINGS: | 28 Drawing Figure(s); 18 Drawing Page(s) | | |
| LINE COUNT: | 3615 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Vitamin B.sub.12 receptor modulating agents capable of modulating cell surface receptors by affecting the cell surface receptor trafficking pathway are disclosed. The vitamin B.sub.12 receptor modulating agents are comprised of a covalently bound rerouting moiety and targeting moiety linked by a water-solublizing linker.

L6 ANSWER 30 OF 68 USPATFULL
ACCESSION NUMBER: 1998:82596 USPATFULL
TITLE: Method of altering blood sugar levels using non-transformed human pancreatic cells that have been expanded in culture
INVENTOR(S): Coon, Hayden G., Gaithersburg, MD, United States
Ambesi-Impiombato, Francesco Saverio, Tricesimo, Italy
Curcio, Francesco, Pagnacco, Italy
PATENT ASSIGNEE(S): Human Cell Cultures Inc., East Sebago, ME, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 5780299 | | 19980714 |
| APPLICATION INFO.: | US 1995-480027 | | 19950607 (8) |
| RELATED APPLN. INFO.: | Division of Ser. No. US 1993-83772, filed on 30 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-44010, filed on 8 Apr 1993, now abandoned | | |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Lankford, Jr., Leon B. | | |
| ASSISTANT EXAMINER: | Tate, Christopher R. | | |
| LEGAL REPRESENTATIVE: | Bundock, John P. | | |
| NUMBER OF CLAIMS: | 14 | | |
| EXEMPLARY CLAIM: | 1 | | |
| NUMBER OF DRAWINGS: | 18 Drawing Figure(s); 11 Drawing Page(s) | | |
| LINE COUNT: | 1828 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for producing an expanded non-transformed cell culture comprising the steps of: (1) preparing partially purified, minced tissue; (2) concentrating the resulting cells and tissue pieces; (3) resuspending the concentrated tissue cells and pieces in a culture medium capable of supporting sustained cell division that is contained in a culture vessel; (4) incubating the cells; and (5) passaging the cells periodically. The present invention further provides clonal strains of cells derived from the above-mentioned cell culture, medium and conditioned medium designed for the culturing of such cells, including pancreatic, thyroid, parathyroid, and parotid cells, and the use of cultured pancreatic cells to form pancreatic pseudotissues composed of matrix-embedded aggregated (pseudoislets) or individual cells, to treat blood sugar disorders in mammals, and to test for cytotoxicity and autoimmune activities with reference to pancreatic endocrine cells.

L6 ANSWER 31 OF 68 USPATFULL
ACCESSION NUMBER: 1998:39675 USPATFULL
TITLE: Biotinylated cobalamins
INVENTOR(S): Wilbur, D. Scott, Edmonds, WA, United States
Pathare, Pradip M., Seattle, WA, United States
Morgan, Jr., A. Charles, Camino Island, WA, United States
PATENT ASSIGNEE(S): University of Washington, Seattle, WA, United States (U.S. corporation)
Receptagen Corp., Edmonds, WA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 5739287 | | 19980414 |
| APPLICATION INFO.: | US 1995-406192 | | 19950316 (8) |

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-224831, filed on 8 Apr 1994, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Russel, Jeffrey E.
LEGAL REPRESENTATIVE: Christensen O'Connor Johnson & Kindness PLLC
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 28 Drawing Figure(s); 18 Drawing Page(s)
LINE COUNT: 3099
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A biotinylated cobalamin, formed from a vitamin B.sub.12 molecule coupled to a biotin molecule, is disclosed. In a preferred embodiment, the vitamin B.sub.12 molecule is cyanocobalamin. The biotin molecule can also be coupled to a rerouting moiety, optionally through a biotin binding protein such as avidin or streptavidin. The biotinylated cobalamin binds to a cell surface receptor, is invaginated, and once internalized affects the receptor trafficking pathway.

L6 ANSWER 32 OF 68 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 1998341676 EMBASE
TITLE: Transmethylation reactions and autoradiographic distribution of vitamin B12: Effects of clioquinol treatment in mice.
AUTHOR: Yassin M.S.; Ekblom J.; Lofberg C.; Oreland L.
CORPORATE SOURCE: L. Oreland, Dept. of Neuroscience (Pharmacology), Biomedical Center, Uppsala University, Box 593, S-751 24 Uppsala, Sweden
SOURCE: Japanese Journal of Pharmacology, (1998) 78/1 (55-61). Refs: 23
ISSN: 0021-5198 CODEN: JJPAAZ
COUNTRY: Japan
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 030 Pharmacology
037 Drug Literature Index
052 Toxicology
LANGUAGE: English
SUMMARY LANGUAGE: English
AB The catastrophic epidemic of subacute myelo-optic neuropathy (SMON) affected Japan around 1970 with thousands of victims. The cause was attributed to high doses of locally acting oxyquinolines. It has been speculated that oxyquinoline derivatives of the clioquinol type can disturb the retention of vitamin B12 through **chelation** of Co2+. In the present paper, possible effects of clioquinol on the uptake and tissue distribution of [57Co]-cyanocobalamin have been studied in mice. In vivo experiments showed markedly decreased accumulation of **radiolabelled** vitamin B12 in the kidney and skin in animals that were pre-treated with clioquinol. The chloroform:water partition coefficients for [57Co]-cyanocobalamin in the presence or absence of clioquinol were also determined. No statistically significant alterations in the partition coefficient for [57Co]-cyanocobalamin in the presence of clioquinol was evident, indicating that clioquinol does not bind cobalt. In addition, transmethylation reactions in the CNS in mice treated with clioquinol were studied. Specific activities of methionine adenosyltransferase, and S-adenosylhomocysteine levels were not affected. In contrast, clioquinol treatment caused a significant increase in the levels of S-adenosylmethionine in the brain. The data of the present study show that clioquinol treatment can affect the accumulation of vitamin B12 in the kidney and the skin but not in the brain. These results do not support the hypothesis that clioquinol causes its damage to the nervous system by a direct chemical interaction with vitamin B12.

L6 ANSWER 33 OF 68 USPATFULL
ACCESSION NUMBER: 97:106797 USPATFULL
TITLE: Anti-receptor and growth blocking antibodies to the vitamin B.sub.12 /transcobalamin II receptor and binding sites
INVENTOR(S): Morgan, Jr., Alton Charles, Edmonds, WA, United States
PATENT ASSIGNEE(S): Receptagen Corporation, Edmonds, WA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 5688504 | | 19971118 |
| APPLICATION INFO.: | US 1994-306504 | | 19940913 (8) |

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-880540, filed on 8 May 1992, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nucker, Christine M.
ASSISTANT EXAMINER: Stucker, Jeffrey
LEGAL REPRESENTATIVE: Seed and Berry LLP
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 1860
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB There is disclosed anti-receptor and growth blocking agents to the vitamin B.sub.12 /transcobalamin II receptor and binding sites. The anti-receptor and growth blocking agents antagonize or modulate the vitamin B.sub.12 /transcobalamin II receptor or binding sites, causing cellular depletion of vitamin B.sub.12, thus preventing or inhibiting cell division or causing apoptosis. Anti-receptor and growth blocking agents of the present invention include proteins (such as antibodies and antibody derivatives), **peptides** and small organic molecules. In a preferred embodiment, the anti-receptor agent is an antibody to the vitamin B.sub.12 /transcobalamin II receptor.

L6 ANSWER 34 OF 68 USPATFULL
ACCESSION NUMBER: 97:91199 USPATFULL
TITLE: Nanoparticles containing an active substance and a ketalized polytartramidic acid, process for their preparation, and use thereof
INVENTOR(S): Ahlers, Michael, Mainz, Germany, Federal Republic of
Walch, Axel, Frankfurt am Main, Germany, Federal Republic of
Seipke, Gerhard, Hofheim, Germany, Federal Republic of
Russell-Jones, Gregory, Middel Cove, Australia
PATENT ASSIGNEE(S): Hoechst Aktiengesellschaft, Frankfurt am Main, Germany,
Federal Republic of (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 5674531 | | 19971007 |
| APPLICATION INFO.: | US 1995-399474 | | 19950307 (8) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | DE 1994-4407898 | 19940309 |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Spear, James M.
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 571
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Nanoparticles containing an active substance and a ketalized polytartramidic acid, process for their preparation, and use thereof. Nanoparticles containing an active substance and a ketalized polytartramidic acid are suitable as vehicles for active substances, in particular for **peptides** and proteins. Processes for the preparation of the nanoparticles are described.

L6 ANSWER 35 OF 68 USPATFULL
ACCESSION NUMBER: 97:83944 USPATFULL
TITLE: Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
INVENTOR(S): Shapiro, Howard K., 214 Price Ave. F32, Narberth, PA, United States 19072

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 5668117 | | 19970916 |
| APPLICATION INFO.: | US 1993-62201 | | 19930629 (8) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 1993-26617, filed on 23 Feb 1993, now abandoned which is a continuation of Ser. No. US 1991-660561, filed on 22 Feb 1991, now abandoned | | |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kight, John
ASSISTANT EXAMINER: Leary, Louise
LEGAL REPRESENTATIVE: Perrella, D. J.
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
LINE COUNT: 3963
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Therapeutic compositions comprising an effective amount of at least one carbonyl trapping agent alone or in combination with a therapeutically effective of a co-agent or medicament are disclosed. The compositions are used to treat a mammal suffering from a neurological disease characterized by covalent bond crosslinking between the nerve cells, other cellular structures and their intracellular and extracellular components, with disease induced carbonyl-containing aliphatic or aromatic hydrocarbons present in mammals.

L6 ANSWER 36 OF 68 USPATFULL
ACCESSION NUMBER: 97:78345 USPATFULL
TITLE: Nucleophilic polysubstituted aryl acridinium ester conjugates and syntheses thereof
INVENTOR(S): Law, Say-Jong, Westwood, MA, United States
PATENT ASSIGNEE(S): Chiron Diagnostics Corporation, Walpole, MA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 5663074 | | 19970902 |
| APPLICATION INFO.: | US 1993-32947 | | 19930317 (8) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 1992-871601, filed on 17 Apr 1992 which is a continuation of Ser. No. US 1988-249620, filed on 26 Sep 1988, now abandoned | | |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Woodward, Michael P.
LEGAL REPRESENTATIVE: Morgenstern, Arthur S., Blackburn, Robert P., Klee, Maurice M.
NUMBER OF CLAIMS: 53
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 1554
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to novel nucleophilic polysubstituted aryl acridinium conjugates and the methods for preparation thereof. The novel
nucleophilic polysubstituted aryl acridinium conjugates are useful in biological assays, including novel assays for the determination of Vitamin B.sub.12, folate, cortisol, estradiol, and thromboxane B.sub.2.

L6 ANSWER 37 OF 68 USPATFULL
ACCESSION NUMBER: 97:59097 USPATFULL
TITLE: Method for preparing an expanded culture and clonal strains of pancreatic, thyroid or parathyroid cells
INVENTOR(S): Coon, Hayden G., Gaithersburg, MD, United States
Ambesi-Impiombato, Francesco Saverio, Tricesimo, Italy
Curcio, Francesco, Pagnacco, Italy
PATENT ASSIGNEE(S): Human Cell Cultures, Inc., Gaithersburg, MD, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 5646035 | | 19970708 |
| APPLICATION INFO.: | US 1995-480149 | | 19950607 (8) |
| RELATED APPLN. INFO.: | Continuation of Ser. No. US 1993-83772, filed on 30 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-44010, filed on 8 Apr 1993, now abandoned | | |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Rollins, John W.
ASSISTANT EXAMINER: Larson, Kristin
LEGAL REPRESENTATIVE: Leydig, Voit & Mayer, Ltd.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 1831
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a method for producing an expanded non-transformed cell culture comprising the steps of: (1) preparing partially purified, minced tissue; (2) concentrating the resulting cells
and tissue pieces; (3) resuspending the concentrated tissue cells and pieces in a culture medium capable of supporting sustained cell division
that is contained in a culture vessel; (4) incubating the cells; and (5)
passaging the cells periodically. The present invention further provides
clonal strains of cells derived from the above-mentioned cell culture, medium and conditioned medium designed for the culturing of such cells, including pancreatic, thyroid, parathyroid, and parotid cells, and the use of cultured pancreatic cells to form pancreatic pseudotissues composed of matrix-embedded aggregated (pseudoislets) or individual cells, to treat blood sugar disorders in mammals, and to test for cytotoxicity and autoimmune activities with reference to pancreatic endocrine cells.

L6 ANSWER 38 OF 68 MEDLINE
ACCESSION NUMBER: 1998012901 MEDLINE
DOCUMENT NUMBER: 98012901 PubMed ID: 9352852
TITLE: Apical expression of functional asialoglycoprotein receptor
in the human intestinal cell line HT-29.
AUTHOR: Mu J Z; Gordon M; Shao J S; Alpers D H
CORPORATE SOURCE: Department of Internal Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA.
CONTRACT NUMBER: PO1-33487
SOURCE: GASTROENTEROLOGY, (1997 Nov) 113 (5) 1501-9.
Journal code: FH3; 0374630. ISSN: 0016-5085.
PUB. COUNTRY: United States
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 199711
ENTRY DATE: Entered STN: 19971224
Last Updated on STN: 19971224
Entered Medline: 19971113
AB BACKGROUND & AIMS: The asialoglycoprotein receptor localizes to the basolateral membrane of hepatocytes and to the apical membrane of enterocytes. The aim of this study was to examine HT-29 cells as a polarized cell model for studying apically localized endogenous asialoglycoprotein receptor. METHODS: Subunits H1 and H2 (human) were detected by Western blot and immunoprecipitated using subunit-specific antisera against hepatic receptor **peptides**. Receptor function was assessed by uptake of iodinated asialo-orosomucoid, immunoglobulin (Ig) A1, and haptocorrin. Immunocytochemistry was analyzed by standard light and confocal microscopy. RESULTS: Receptor content of the minor subunit, H2, was predominant. HT-29 cells mediated specific uptake and degradation of 125I-asialo-orosomucoid. A high-affinity (0.6 x 10(-9) mmol/L) and a low-affinity binding site were present. The specific **ligand** binding capacity of the apical surface was approximately twice that of the basolateral surface. Immunocytochemistry revealed a predominant apical membrane location of the minor receptor subunit, with some intracellular receptor. The apical H2 subunit was preferentially labeled with **amino acid** precursors compared with basolaterally located subunit. Human IgA1 bound specifically to HT-29 cells with a molar ratio of 0.26 compared with asialo-orosomucoid; porcine
haptocorrin bound with a molar ratio of 1.35. CONCLUSIONS: HT-29 cells produce a functional apically located asialoglycoprotein receptor and provide a model for receptor trafficking in the enterocyte.

L6 ANSWER 39 OF 68 USPATFULL

ACCESSION NUMBER: 96:99222 USPATFULL
TITLE: Combination medications containing alpha-lipoic acid and related
INVENTOR(S): Weischer, Carl-Heinrich, Bonn, Germany, Federal Republic of
Ulrich, Heinz, Niedernberg, Germany, Federal Republic of
Wessel, Klaus, Frankfurt, Germany, Federal Republic of
PATENT ASSIGNEE(S): Asta Medica Aktiengesellschaft, Dresden, Germany, Federal Republic of (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 5569670 | | 19961029 |
| APPLICATION INFO.: | US 1995-404153 | | 19950314 (8) |
| RELATED APPLN. INFO.: | Division of Ser. No. US 1994-197643, filed on 10 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-71259, filed on 4 Jun 1993, now abandoned | | |
| PRIORITY INFORMATION: | DE 1992-4218572 | | 19920605 |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Dees, Jos e G. | | |
| ASSISTANT EXAMINER: | Lambkin, Deborah | | |
| LEGAL REPRESENTATIVE: | Cushman Darby & Cushman, LLP | | |
| NUMBER OF CLAIMS: | 1 | | |
| EXEMPLARY CLAIM: | 1 | | |
| LINE COUNT: | 1013 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical composition containing alpha-lipoic acid, dihydrolipoic acid, metabolites of alpha-lipoic acid (inter alia bisnortetralipoic acid and tetranorlipoic acid), optical isomers R- and S- forms of alpha-lipoic acid in oxidized and reduced form together with a vitamin, especially vitamins A, B1, B2, B6, B12, C and E and their pharmaceutically acceptable salts. The compositions are useful for producing analgesic, anti-inflammatory, antidiabetic, cytoprotective, anti-ulcer, antinecrotic, neuroprotective, detoxifying, anti-ischemic, liver function regulating, anti-allergic, immune-stimulating and antioncogenic effects.

L6 ANSWER 40 OF 68 USPATFULL

ACCESSION NUMBER: 96:65493 USPATFULL
TITLE: Nucleophilic polysubstituted aryl acridinium ester conjugates uses thereof
INVENTOR(S): Law, Say-Jong, Westwood, MA, United States
Chang, Steve C. S., Franklin, MA, United States
Klukas, Carol K., Pittsburgh, PA, United States
Vitkauskas, Christine A., North Attleboro, MA, United States
PATENT ASSIGNEE(S): Ciba Corning Diagnostics Corp., Medfield, MA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 5538901 | | 19960723 |
| APPLICATION INFO.: | US 1994-292946 | | 19940818 (8) |
| RELATED APPLN. INFO.: | Continuation of Ser. No. US 1993-32085, filed on 17 Mar 1993, now abandoned which is a division of Ser. No. US 1992-871601, filed on 17 Apr 1992, now patented, Pat. No. US 5241070, issued on 13 Aug 1993 which is a continuation of Ser. No. US 1988-249620, filed on 26 Sep 1988, now abandoned | | |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Spiegel, Carol A. | | |
| LEGAL REPRESENTATIVE: | Morgenstern, Arthur S., Roesler, Judith A. | | |
| NUMBER OF CLAIMS: | 15 | | |
| EXEMPLARY CLAIM: | 1 | | |
| NUMBER OF DRAWINGS: | 18 Drawing Figure(s); 15 Drawing Page(s) | | |
| LINE COUNT: | 1444 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is directed to the novel assay methods utilizing nucleophilic polysubstituted aryl acridinium ester conjugates as the tracers. Conjugates prepared by covalent coupling of novel nucleophilic polysubstituted aryl acridinium esters with biological compounds including small organic molecules such as Vitamin B12, folate, cortisol, estradiol, and thromboxane B2, were found useful in the development of highly sensitive assays for the analytes of diagnostic interest.

L6 ANSWER 41 OF 68 USPATFULL

ACCESSION NUMBER: 95:64857 USPATFULL
TITLE: Folate immunoassay utilizing folate binding protein in a multiclonal antibody format
INVENTOR(S): Begga, Michael J., Waukegan, IL, United States
Sohn, Linda J., Palatine, IL, United States
Herrmann, Robert J., Gurnee, IL, United States
Hsu, Stephen, Vernon Hills, IL, United States
Hawksworth, David J., Mundelein, IL, United States
Pinkus, Mary S., Chicago, IL, United States
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 5434087 | | 19950718 |
| APPLICATION INFO.: | US 1993-21942 | | 19930224 (8) |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Scheiner, Toni R. | | |
| ASSISTANT EXAMINER: | Parsons, Nancy J. | | |
| LEGAL REPRESENTATIVE: | Weinstein, David L. | | |
| NUMBER OF CLAIMS: | 25 | | |
| EXEMPLARY CLAIM: | 1 | | |
| NUMBER OF DRAWINGS: | 3 Drawing Figure(s); 2 Drawing Page(s) | | |
| LINE COUNT: | 711 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An improved method for performing immunoassays whereby specific binding proteins for vitamin B12, folate and other target analytes are utilized with antibodies with different specificities for the binding proteins. Antibodies bridge the specific binding protein directly or indirectly to a capturable material.

L6 ANSWER 42 OF 68 BIOSIS COPYRIGHT 2001 BIOSIS

ACCESSION NUMBER: 1995:509032 BIOSIS
DOCUMENT NUMBER: PREV199598514082
TITLE: Inhibition of chondrocyte cathepsin B and L activities by insulin-like growth factor-II (IGF-II) and its Ser-29 variant in vitro: Possible role of the mannose 6-phosphate/IGF-II receptor.
AUTHOR(S): De Ceuninck, F.; Poiraudeau, S.; Pagano, M.; Tsagris, L.; Blanchard, O.; Willeput, J.; Corvol, M. (1)
CORPORATE SOURCE: (1) Institut National de la Sante et de la Recherche Medicale, U 30, 149 rue de Sevres, 75743 Paris, Cedex 15 France
SOURCE: Molecular and Cellular Endocrinology, (1995) Vol. 113, No. 2, pp. 205-213.
ISSN: 0303-7207.
DOCUMENT TYPE: Article
LANGUAGE: English

AB Lysosomal enzymes and IGF-II both bind to the mannose 6-phosphate (M6P)/IGF-II receptor. This receptor targets newly synthesized lysosomal enzymes to lysosomes. The functional meaning of IGF-II binding to this receptor is not well known. We have postulated that IGF-II may affect the targeting of lysosomal enzymes in cartilage remodeling. We therefore examined the effect of IGF-II, the Ser-29 IGF-II variant (vIGF-II) and IGF-I on lysosomal cathepsin B and L activities from post-natal rabbit chondrocytes in vitro. This effect was compared with the ability of each **peptide** to stimulate chondrocyte-sulfated proteoglycan synthesis. The sulfating dose-response relationship of the IGF **peptides** corresponded to their relative binding affinities for the type I-IGF receptor (IGF-I gt IGF-II gt vlGF-II). The intracellular cathepsin B and L activities were inhibited in a time- and dose-dependent manner by IGF-II or vlGF-II. Maximal inhibition of cathepsin B and L activities (40 and 30% below controls, respectively) was found after an 8 h treatment with 100 ng/ml IGF-II or vIGF-II. By contrast, IGF-I up to 1 mu-g/ml or insulin up to 2 mu-g/ml had no inhibitory effect. The relative potency pattern corresponded to the binding profile of each **ligand** for the M6P/IGF-II receptor. A treatment of chondrocytes with IGF-I or insulin transiently increased the binding of **radiolabelled** IGF-II at the cell surface to -120% of controls, whereas IGF-II or vIGF-II had no effect. Thus, it is unlikely that the inhibition of lysosomal enzyme activities by IGF-II **peptides** could result from a redistribution of M6P/IGF-II receptors from intracellular compartments to the plasma membrane. We hypothesize that internalized IGF-II **peptides** could occupy the intracellular M6P/IGF-II binding sites required for the targeting of cathepsins B and L to lysosomes.

L6 ANSWER 43 OF 68 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1994:442743 CAPLUS
DOCUMENT NUMBER: 121:42743
TITLE: Microparticle formulations containing biodegradable mixed polymers
INVENTOR(S): Fritzsch, Thomas; Heldmann, Dieter; Weitschies, Werner
PATENT ASSIGNEE(S): Schering A.-G., Germany
SOURCE: Ger. Offen., 8 pp.
CODEN: GWXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| DE 4232755 | A1 | 19940331 | DE 1992-4232755 | 19920926 |
| WO 9407539 | A1 | 19940414 | WO 1993-EP2422 | 19930908 |
| W: AU, CA, FI, HU, JP, KR, NO, NZ, US | | | | |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| EP 662005 | A1 | 19950712 | EP 1993-919293 | 19930908 |
| EP 662005 | B1 | 19980429 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| HU 71683 | A2 | 19960129 | HU 1995-876 | 19930908 |
| JP 08504398 | T2 | 19960514 | JP 1993-508620 | 19930908 |
| AU 687360 | B2 | 19980226 | AU 1993-49592 | 19930908 |
| AT 165517 | E | 19980515 | AT 1993-919293 | 19930908 |
| ES 2118251 | T3 | 19980916 | ES 1993-919293 | 19930908 |
| ZA 9307099 | A | 19950324 | ZA 1993-7099 | 19930924 |
| CN 1089508 | A | 19940720 | CN 1993-118159 | 19930925 |
| IL 107108 | A1 | 19980104 | IL 1993-107108 | 19930926 |
| FI 9501379 | A | 19950323 | FI 1995-1379 | 19950323 |
| NO 9501138 | A | 19950324 | NO 1995-1138 | 19950324 |
| PRIORITY APPLN. INFO.: | | | DE 1992-4232755 | 19920926 |
| | | | WO 1993-EP2422 | 19930908 |

AB Microcapsules for diagnostic or therapeutic use are prepd. comprising (1) a wall of biopolymer/synthetic polymer interpolymer, which has site-specific phys. properties or bears functional groups for binding e.g. **chelating ligands** or their metal complexes, and (2) an optional core consisting of a gas or therapeutic agent. Thus, an autoclaved gelatin soln. was adjusted to pH 5.0 and stirred with Bu cyanoacrylate to produce air-filled dispersible microparticles [55 mol% gelatin, 45 mol% poly(Bu cyanoacrylate)] for use in contrast media for sonog.

L6 ANSWER 44 OF 68 USPATFULL
ACCESSION NUMBER: 94:88598 USPATFULL
TITLE: Lyophilized **ligand**-receptor complexes for assays and sensors
INVENTOR(S): Ligler, Frances S., Potomac, MD, United States
Whelan, James P., Potomac, MD, United States
PATENT ASSIGNEE(S): The United States of America as Represented by the Secretary of the Navy, Washington, DC, United States (U.S. government)
U.S. Drug Testing, Inc., Rancho Cucamonga, CA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 5354654 | | 19941011 |
| APPLICATION INFO.: | US 1993-92518 | | 19930716 (8) |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Saunders, David | | |
| LEGAL REPRESENTATIVE: | Oblon, Spivak, McClelland, Maier & Neustadt | | |
| NUMBER OF CLAIMS: | 22 | | |
| EXEMPLARY CLAIM: | 1 | | |
| NUMBER OF DRAWINGS: | 2 Drawing Figure(s); 2 Drawing Page(s) | | |
| LINE COUNT: | 1129 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A dry reagent prepared by lyophilizing a labelled **ligand**-immobilized receptor complex or a labelled receptor-immobilized **ligand** complex is, on rehydration, useful for detecting analytes in samples in a variety of displacement assays.

L6 ANSWER 45 OF 68 MEDLINE
ACCESSION NUMBER: 95070174 MEDLINE
DOCUMENT NUMBER: 95070174 PubMed ID: 7979409
TITLE: Effect of processing inhibitors on cobalamin (vitamin B12) transcytosis in polarized opossum kidney cells.
AUTHOR: Ramanujam K S; Seetharam S; Dahms N M; Seetharam B
CORPORATE SOURCE: Department of Medicine, Medical College of Wisconsin, Milwauke 53226.
CONTRACT NUMBER: DK-26638 (NIDDK)
SOURCE: ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, (1994 Nov 15) 315 (1) 8-15.
Journal code: 6SK; 0372430. ISSN: 0003-9861.
PUB. COUNTRY: United States
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199412
ENTRY DATE: Entered STN: 19950110
Last Updated on STN: 19950110
Entered Medline: 19941216

AB The main objectives of the current study were to investigate the effect of tunicamycin and other posttranslational processing inhibitors on the apical brush border expression of intrinsic factor-cobalamin receptor (IFCR) and the apical to basolateral transcytosis of cobalamin (Cbl). Because of the high and selective expression of IFCR in the apical brush border membrane of opossum kidney (OK) cells (K. S. Ramanujam, S. Seetharam, N. Dahms, and B. Seetharam, (1991) J. Biol. Chem. 266, 13135-13140), we have used cultured OK cells to address these issues. When polarized OK cells grown on culture inserts were incubated with tunicamycin, deoxynojirimycin, swainsonine, or cerulenin, the surface binding of the **ligand**, intrinsic factor-[56Co]Cbl was inhibited by tunicamycin but not by the other inhibitors. However, Cbl transcytosis was inhibited by both tunicamycin and cerulenin but not with deoxynojirimycin or swainsonine. Incubation of cells with tunicamycin decreased the half-life of IFCR from 48 to 24 h, thus causing faster degradation and depletion of the surface receptor. Incubation of cells with cerulenin resulted in the intralysosomal retention of internalized Cbl. Mature receptor labeled with either [35S]methionine or [3H]mannose was sensitive to digestion with both endoglycosidase H and **peptide** N-glycosidase F and revealed the presence of two or three N-linked oligosaccharides of the high mannose or hybrid type. Metabolic labeling of OK cells with [3H]palmitic acid revealed that IFCR was palmitoylated and the label was sensitive to treatment with hydroxylamine. Based on these results we suggest that IFCR expression in the apical membrane and Cbl transcytosis in polarized OK cells are regulated by core N-glycosylation but not by further processing of the terminal sugars. In addition, we also suggest that the inhibition of Cbl transcytosis by cerulenin is due to inhibition of postinternalization events.

L6 ANSWER 46 OF 68 USPATFULL
ACCESSION NUMBER: 93:72216 USPATFULL
TITLE: Nucleophilic polysubstituted aryl acridinium esters and uses thereof
INVENTOR(S): Law, Say-Jong, Westwood, MA, United States
PATENT ASSIGNEE(S): Ciba Corning Diagnostics Corp., Medfield, MA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 5241070 | | 19930831 |
| APPLICATION INFO.: | US 1992-871601 | | 19920417 (7) |
| DISCLAIMER DATE: | 20070417 | | |
| RELATED APPLN. INFO.: | Continuation of Ser. No. US 1988-249620, filed on 26 Sep 1988, now abandoned | | |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Daus, Donald G. | | |
| LEGAL REPRESENTATIVE: | Morgenstern, Arthur S., Slepchuk, Jr., Nicholas I. | | |
| NUMBER OF CLAIMS: | 3 | | |
| EXEMPLARY CLAIM: | 1 | | |
| NUMBER OF DRAWINGS: | 18 Drawing Figure(s); 15 Drawing Page(s) | | |
| LINE COUNT: | 1023 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to novel nucleophilic polysubstituted aryl acridinium esters and to novel conjugates thereof. The novel nucleophilic polysubstituted aryl acridinium esters and novel conjugates thereof are useful in biological assays, including novel assays for the determination of Vitamin B.sub.12, folate, cortisol, estradiol, and thromboxane B.sub.2.

L6 ANSWER 47 OF 68 USPATFULL
ACCESSION NUMBER: 93:61007 USPATFULL
TITLE: Method for the prescreening of drugs targeted to the V3
hypervariable loop of the HIV-1 envelope glycoprotein gp 120
INVENTOR(S): Neurath, Alexander R., 230 E. 79th St., New York, NY, United States 10021
Strick, Nathan, 3243 Lawrence Ave., Oceanside, NY, United States 11572
Haberfield, Paul, 1666 52nd St., Brooklyn, NY, United States 11204
Jiang, Shibo, 316 W. 95th St. Apr. 525, New York, NY, United States 10025

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 5230998 | | 19930727 | |
| APPLICATION INFO.: | US 1991-735640 | | 19910725 | (7) |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nucker, Christine M.
ASSISTANT EXAMINER: Stucker, Jeffrey
LEGAL REPRESENTATIVE: Frishauf, Holtz, Goodman & Woodward
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 7
NUMBER OF DRAWINGS: 19 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 1592
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for the rapid screening of a drug targeted to the V3 hypervariable loop of the human immunodeficiency virus type 1 or type 2 envelope glycoprotein gp 120 comprising measuring the inhibitory effect of the drug on the interaction between gp 120 (or an antigen comprising the V3 hypervariable loop of HIV 1 gp 120 or HIV 2 gp 120) and antibodies specific for the V3 hypervariable loop, and anti-HIV chemotherapy with drugs binding to the V3 hypervariable loop.

L6 ANSWER 48 OF 68 USPATFULL
ACCESSION NUMBER: 93:79787 USPATFULL
TITLE: Method and composition for double receptor, specific binding assays
INVENTOR(S): Bunting, James R., Washington, DC, United States
PATENT ASSIGNEE(S): Baxter Diagnostics Inc., Deerfield, IL, United States (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 34394 | | 19930928 | |
| | US 4271140 | | 19810602 | (Original) |
| APPLICATION INFO.: | US 1990-629020 | | 19901218 | (7) |
| | US 1978-930130 | | 19780801 | (Original) |

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1989-353814, filed on 2 May 1989 And a continuation-in-part of Ser. No. US 1978-871478, filed on 23 Jan 1978, now abandoned
DOCUMENT TYPE: Reissue
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nucker, Christine M.
ASSISTANT EXAMINER: Preston, David R.
LEGAL REPRESENTATIVE: Patterson & Keough
NUMBER OF CLAIMS: 46
EXEMPLARY CLAIM: 1,46
LINE COUNT: 1161
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The performance of double receptor, specific binding assays is improved by use of a receptor complex having the structure

A.sub.BL (BL).sub.n A.sub.1

wherein BL is a binding **ligand**, A.sub.BL is a receptor specific for binding **ligand**, A.sub.1 is a receptor, BL is covalently bonded to A.sub.1 and A.sub.BL is reversibly bonded to BL. Generally A.sub.BL is absorbed onto an insoluble surface and A.sub.1 is an antibody to the substance being assayed. The complex has particular utility in coated tube and rechargeable radioimmunoassay systems.

L6 ANSWER 49 OF 68 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1992:620158 CAPLUS
DOCUMENT NUMBER: 117:220158
TITLE: A system for enhanced in vivo clearance of diagnostic and/or therapeutic agents by extracorporeal depletion
INVENTOR(S): Nilsson, Rune; Lindgren, Lars; Norrgren, Kristina; Sandberg, Bengt; Sjoegren, Hans Olof; Strand, Sven Erik
PATENT ASSIGNEE(S): Swed.
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9212730 | A1 | 19920806 | WO 1992-SE20 | 19920115 |
| W: CA, FI, JP, NO, US | | | | |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE | | | | |
| SE 9100142 | A | 19920718 | SE 1991-142 | 19910117 |
| CA 2100256 | AA | 19920718 | CA 1992-2100256 | 19920115 |
| EP 567514 | A1 | 19931103 | EP 1992-903020 | 19920115 |
| EP 567514 | B1 | 19990331 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE | | | | |
| JP 06504542 | T2 | 19940526 | JP 1992-503119 | 19920115 |
| AT 178214 | E | 19990415 | AT 1992-903020 | 19920115 |
| ES 2130167 | T3 | 19990701 | ES 1992-903020 | 19920115 |
| US 6251394 | B1 | 20010626 | US 1993-90047 | 19931012 |
| PRIORITY APPLN. INFO.: | | | SE 1991-142 A | 19910117 |
| | | | WO 1992-SE20 W | 19920115 |

AB Non-tissue-bound targeting mols., selective for certain tissues or cells, intended for diagnostic and/or therapeutic applications are removed from blood or reduced to a lower concn. by an extracorporeal system contg. immobilized agents (e.g. receptors) which selectively bind the targeting mols. Targeting mols. are antibodies or their fragments conjugated with cytotoxic drugs, **radioisotopes** or activators of prodrugs, i.e. enzymes.

L6 ANSWER 50 OF 68 BIOSIS COPYRIGHT 2001 BIOSIS
ACCESSION NUMBER: 1993:34784 BIOSIS
DOCUMENT NUMBER: PREV199395022984
TITLE: IGF-I binding and IGF-I mRNA expression in the post-ischemic regenerating rat kidney.
AUTHOR(S): Matejka, Goran L. (1); Jennische, Eva
CORPORATE SOURCE: (1) Dep. of Histol., Univ. of Goteborg, Goteborg Sweden
SOURCE: Kidney International, (1992) Vol. 42, No. 5, pp. 1113-1123.
ISSN: 0085-2538.
DOCUMENT TYPE: Article
LANGUAGE: English
AB The localization of IGF-I **peptide** and IGF-I mRNA was investigated in the post-ischemic regeneration rat kidney using immunohistochemistry and non-**radioactive** in situ hybridization techniques. In addition, the distribution and relative quantity of IGF-I binding sites were studied by autoradiographic **ligand**-binding techniques. Two and three days after the injury, morphological signs of an intense regenerative activity was evident. By this time a substantial number of the regenerating cells were stained with a monoclonal antibody against the M1 subunit of ribonucleotide reductase, a proliferative marker used. Low proliferative tubular cells, replacing those that had been injured, were seen lining the tubular basement membrane. By seven days, the morphology in the cortex was quite normalized while cells of S3 segments in the outer medulla remained dedifferentiated. The regenerative cells expressed IGF-I **peptide** and IGF-I mRNA in a transient manner and this was found to correlate better to cell differentiation than cell division. In addition, non-tubular cells, predominantly macrophages, expressed both the IGF-I **peptide** and the mRNA. The IGF-I binding was significantly increased in the regenerative zone at all times studied and began to decline at day seven. The binding characteristics were found to be compatible with binding to the IGF-I receptor. Altogether, these findings provide circumstantial evidence that IGF-I is of tropic importance in the regeneration of renal tubular cells. The data are compatible with a local production and action of IGF-I, suggesting an autocrine and/or paracrine mode of action during the regenerative process.

L6 ANSWER 51 OF 68 USPATFULL
ACCESSION NUMBER: 91:60741 USPATFULL
TITLE: Redox polymerization diagnostic test composition and method for immunoassay and nuclei acid assay
INVENTOR(S): Oster, Gerald, 241 W. 11th St., New York, NY, United States 10014
Davis, Baruch J., Mount Sinai Medical Center, 1 Gustav Levy Pl., New York, NY, United States 10029

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 5035997 | | 19910730 |
| APPLICATION INFO.: | US 1989-312525 | | 19890217 (7) |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Marschel, Ardin H.
LEGAL REPRESENTATIVE: Sprung Horn Kramer & Woods
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 747
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A diagnostic test composition for detecting and measuring an analyte possessing biologic activity, the composition comprising

(a) A redox catalyst system capable of converting a monomer to a polymer, the monomer capable of undergoing addition polymerization, the redox catalyst system comprising one or more chemical moieties with

1) the analyte comprising at least one such moiety or

2) in the case that the analyte lacks a redox catalyst property, the analyte is linked by a specific **ligand** to at least one such moiety or is linked by the specific **ligand** to a generator of at least one such moiety, and

(b) at least one monomer capable of undergoing addition polymerization.

L6 ANSWER 52 OF 68 USPATFULL
ACCESSION NUMBER: 91:42637 USPATFULL
TITLE: Photopolymerization diagnostic test composition and method for immunoassay and nucleic acid assay
INVENTOR(S): Oster, Gerald, 241 W. 11th St., New York, NY, United States 10014
Davis, Baruch J., Mount Sinai Medical Center, 1 Gustave
Levy Pl., New York, NY, United States 10029

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 5019496 | | 19910528 |
| APPLICATION INFO.: | US 1989-312544 | | 19890217 (7) |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Marschel, Ardin H.
LEGAL REPRESENTATIVE: Sprung Horn Kramer & Woods
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
LINE COUNT: 1091
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A diagnostic test composition for detecting and measuring an analyte possessing biologic activity comprising

(a) a photocatalyst system capable of converting a monomer to a polymer upon exposure to light, the monomer capable of undergoing addition polymerization, the photocatalyst system comprising one or more chemical
moieties, with

(1) the analyte comprising at least one such moiety or generating at least one such moiety or

(2) in the case that the analyte lacks a photocatalyst property, the analyte is linked by a specific **ligand** to at least one such moiety or is linked by the specific **ligand** to a generator of at least one such moiety and

(b) at least one monomer capable of undergoing addition polymerization.

L6 ANSWER 53 OF 68 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 91108459 EMBASE
DOCUMENT NUMBER: 1991108459
TITLE: **Ligand**-exchange radiochromatographic resolution of [3H]DL-valine, [3H]DL-leucine and [3H]DL-methionine using a reverse-phase column in the presence of cupric acetate and GMP or cyanocobalamin.
AUTHOR: Fukuhara T.; Isoyama M.; Tanaka M.; Yuasa S.
CORPORATE SOURCE: Department of Biology, College of General Education, Osaka University,Osaka 560, Japan
SOURCE: Applied Radiation and Isotopes, (1991) 42/5 (457-462). ISSN: 0883-2889 CODEN: ARISEF
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 023 Nuclear Medicine
029 Clinical Biochemistry
LANGUAGE: English
SUMMARY LANGUAGE: English
AB [3H]DL-valine, [3H]DL-leucine and [3H]DL-methionine were resolved using **ligand**-exchange chromatography (reverse-phase) in the presence of cupric acetate [Cu(II)], and 5'-guanosine monophosphate or cyanocobalamin.
The assignment of the resolved enantiomers was carried out by means of co-chromatography with non-labeled DL-**amino acids** after modifying them with fluorodinitrobenzene. The optical purity of the enantiomers was estimated to be greater than 99%. The resolved enantiomers
were subjected to bioassay, which showed that the enantiomers were biochemically active.

L6 ANSWER 54 OF 68 USPATFULL
ACCESSION NUMBER: 90:54554 USPATFULL
TITLE: Assay for sulfhydryl **amino acids** and methods for detecting and distinguishing cobalamin and folic acid deficency
INVENTOR(S): Allen, Robert H., Englewood, CO, United States
Stabler, Sally P., Denver, CO, United States
Lindenbaum, John, New York, NY, United States
PATENT ASSIGNEE(S): University Patents, Inc., Westport, CT, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 4940658 | | 19900710 |
| APPLICATION INFO.: | US 1986-933553 | | 19861120 (6) |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kepplinger, Esther M.
ASSISTANT EXAMINER: Scheiner, Toni R.
LEGAL REPRESENTATIVE: Yahwak & Associates
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 18
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 2375
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method for determining levels of sulfhydryl **amino acids**, particularly total homocysteine levels in samples of body tissue from warm-blooded animals, methods of detecting cobalamin and folic acid deficiency using an assay for total homocysteine levels, and methods for distinguishing cobalamin from folic acid deficiency using an
assay for total homocysteine levels in conjunction with an assay for methylmalonic acid.

L6 ANSWER 55 OF 68 USPATFULL
ACCESSION NUMBER: 90:15471 USPATFULL
TITLE: Cascade immunoassay by multiple binding reactions
INVENTOR(S): Mapes, James P., Raleigh, NC, United States
Hoke, Randal A., Cary, NC, United States
PATENT ASSIGNEE(S): Becton, Dickinson and Company, Franklin Lakes, NJ, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 4904583 | | 19900227 |
| APPLICATION INFO.: | US 1987-53896 | | 19870526 (7) |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Warden, Robert J.
ASSISTANT EXAMINER: Spiegel, Jack
LEGAL REPRESENTATIVE: Brown, Richard E.
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 785
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for enzyme immunoassay includes contacting under binding conditions a liquid suspected of containing an analyte, an antianalyte affixed to a solid support and a tracer having an enzyme conjugated thereto. A bound fraction is separated from the liquid and incubated in a second liquid with a masked **ligand**. The masked **ligand** is converted by the enzyme on the bound fraction to give free lignad which binds to an antiligand. A signal system, such as a signal enzyme and substrate therefor, or a label-loaded vesicle and vesicle lysing agent, is added to generate a signal used to detect or measure the analyte in the liquid. The invention includes a kit of materials useful in performing the assay of the invention.

L6 ANSWER 56 OF 68 USPATFULL
ACCESSION NUMBER: 87:69949 USPATFULL
TITLE: Enzymatic reactions using magnetic particles
INVENTOR(S): Whitehead, Roy A., Hingham, MA, United States
Chagnon, Mark S., Lowell, MA, United States
Groman, Ernest V., Brookline, MA, United States
Josephson, Lee, Arlington, MA, United States
PATENT ASSIGNEE(S): Advanced Magnetics, Inc., Cambridge, MA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 4698302 | | 19871006 |
| APPLICATION INFO.: | US 1985-744457 | | 19850613 (6) |
| RELATED APPLN. INFO.: | Division of Ser. No. US 1983-493991, filed on 12 May 1983, now patented, Pat. No. US 4554088 | | |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Foelak, Morton
ASSISTANT EXAMINER: Nutter, Nathan M.
LEGAL REPRESENTATIVE: Pennie & Edmonds
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1464
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process is provided for the preparation of magnetic particles to which
a wide variety of molecules may be coupled. The magnetic particles can be dispersed in aqueous media without rapid settling and conveniently reclaimed from media with a magnetic field. Preferred particles do not become magnetic after application of a magnetic field and can be redispersed and reused. The magnetic particles are useful in biological systems involving separations.

L6 ANSWER 57 OF 68 USPATFULL
ACCESSION NUMBER: 87:66802 USPATFULL
TITLE: Magnetic particles for use in separations
INVENTOR(S): Chagnon, Mark S., Lowell, MA, United States
Groman, Ernest V., Brookline, MA, United States
Josephson, Lee, Arlington, MA, United States
Whitehead, Roy A., Hingham, MA, United States
PATENT ASSIGNEE(S): Advanced Magnetics Inc., Cambridge, MA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 4695393 | | 19870922 |
| APPLICATION INFO.: | US 1985-744435 | | 19850613 (6) |
| RELATED APPLN. INFO.: | Division of Ser. No. US 1983-493991, filed on 12 May 1983, now patented, Pat. No. US 4554088 | | |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Foelak, Morton
ASSISTANT EXAMINER: Nutter, Nathan M.
LEGAL REPRESENTATIVE: Pennie & Edmonds
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1514
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process is provided for the preparation of magnetic particles to which
a wide variety of molecules may be coupled. The magnetic particles can be dispersed in aqueous media without rapid settling and conveniently reclaimed from media with a magnetic field. Preferred particles do not become magnetic after application of a magnetic field and can be redispersed and reused. The magnetic particles are useful in biological systems involving separations.

L6 ANSWER 58 OF 68 USPATFULL
ACCESSION NUMBER: 87:66801 USPATFULL
TITLE: Magnetic particles for use in separations
INVENTOR(S): Whitehead, Roy A., Hingham, MA, United States
Chagnon, Mark S., Lowell, MA, United States
Groman, Ernest V., Brookline, MA, United States
Josephson, Lee, Arlington, MA, United States
PATENT ASSIGNEE(S): Advanced Magnetics Inc., Cambridge, MA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 4695392 | | 19870922 |
| APPLICATION INFO.: | US 1985-744434 | | 19850613 (6) |
| RELATED APPLN. INFO.: | Division of Ser. No. US 1983-493991, filed on 12 May 1983, now patented, Pat. No. US 4554088 | | |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kight, John
ASSISTANT EXAMINER: Nutter, Nathan M.
LEGAL REPRESENTATIVE: Pennie & Edmonds
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1459
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process is provided for the preparation of magnetic particles to which
a wide variety of molecules may be coupled. The magnetic particles can be dispersed in aqueous media without rapid settling and conveniently reclaimed from media with a magnetic field. Preferred particles do not become magnetic after application of a magnetic field and can be redispersed and reused. The magnetic particles are useful in biological systems involving separations.

L6 ANSWER 59 OF 68 USPATFULL
ACCESSION NUMBER: 87:41600 USPATFULL
TITLE: Magnetic particles for use in separations
INVENTOR(S): Josephson, Lee, Arlington, MA, United States
PATENT ASSIGNEE(S): Advanced Magnetics, Inc., Cambridge, MA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 4672040 | | 19870609 |
| APPLICATION INFO.: | US 1985-749692 | | 19850628 (6) |

DISCLAIMER DATE: 20021119
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1983-493991, filed on 12 May 1983, now patented, Pat. No. US 4554088 And Ser. No. US 1985-744351, filed on 13 Jun 1985, now patented, Pat. No. US 4628037 And Ser. No. US 1985-744435, filed on 13 Jun 1985 And Ser. No. US 1985-744434, filed on 13 Jun 1985 And Ser. No. US 1985-744457, filed on 13 Jun 1985
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nucker, Christine M.
ASSISTANT EXAMINER: Wieder, Stephen C.
LEGAL REPRESENTATIVE: Pennie & Edmonds
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1770
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods are provided for the use of magnetically responsive particles in systems in which the separation of certain molecules, macromolecules and cells from the surrounding medium is desirable. The magnetically responsive particles may be coupled to a wide variety of molecules. The magnetic particles can be dispersed in aqueous media without rapid settling and conveniently reclaimed from media with a magnetic field. Preferred particles do not become magnetic after application of a magnetic field and can be redispersed and reused.

L6 ANSWER 60 OF 68 USPATFULL
ACCESSION NUMBER: 87:41588 USPATFULL
TITLE: Compositions and method for simultaneous multiple assay of analytes using **radioisotope** **chelate** labels
INVENTOR(S): Olson, Douglas R., Doylestown, PA, United States
PATENT ASSIGNEE(S): ICN Micromedic Systems, Inc., Costa Mesa, CA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 4672028 | | 19870609 |
| APPLICATION INFO.: | US 1984-612979 | | 19840523 (6) |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nucker, Christine M.
LEGAL REPRESENTATIVE: Lyon & Lyon
NUMBER OF CLAIMS: 47
EXEMPLARY CLAIM: 1
LINE COUNT: 784
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds useful in a simultaneous multiple assay for analytes such as steroids, proteins, **peptides**, carbohydrates or drugs. The compound or compounds are prepared by labelling an individual analyte with a **radioisotope** through a **chelating** agent to form a coordinated compound. The assay uses one or more **chelated** labelled analytes with one or more labelled analytes wherein each **radioisotope** is different.

L6 ANSWER 61 OF 68 USPATFULL
ACCESSION NUMBER: 86:69734 USPATFULL
TITLE: Binding assays employing magnetic particles
INVENTOR(S): Chagnon, Mark S., Lowell, MA, United States
Groman, Ernest V., Brookline, MA, United States
Josephson, Lee, Arlington, MA, United States
Whitehead, Roy A., Hingham, MA, United States
PATENT ASSIGNEE(S): Advanced Magnetics, Inc., Cambridge, MA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 4628037 | | 19861209 |
| APPLICATION INFO.: | US 1985-744351 | | 19850613 (6) |

RELATED APPLN. INFO.: Division of Ser. No. US 1983-493991, filed on 12 May 1983, now patented, Pat. No. US 4554488
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nucker, Christine M.
ASSISTANT EXAMINER: Wieder, Stephen C.
LEGAL REPRESENTATIVE: Pennie & Edmonds
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1495
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process is provided for the preparation of magnetic particles to which a wide variety of molecules may be coupled. The magnetic particles can be dispersed in aqueous media without rapid settling and conveniently reclaimed from media with a magnetic field. Preferred particles do not become magnetic after application of a magnetic field and can be redispersed and reused. The magnetic particles are useful in biological systems involving separations.

L6 ANSWER 62 OF 68 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1986:84931 CAPLUS
DOCUMENT NUMBER: 104:84931
TITLE: Simultaneous multiple assays and compounds and compositions useful in them
INVENTOR(S): Olson, Douglas Richard
PATENT ASSIGNEE(S): Micromedic Systems, Inc., USA
SOURCE: Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| EP 165716 | A1 | 19851227 | EP 1985-303564 | 19850521 |
| EP 165716 | B1 | 19900131 | | |
| R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE | | | | |
| US 4672028 | A | 19870609 | US 1984-612979 | 19840523 |
| AT 50066 | E | 19900215 | AT 1985-303564 | 19850521 |
| AU 8542798 | A1 | 19851128 | AU 1985-42798 | 19850523 |
| AU 582970 | B2 | 19890413 | | |
| JP 61000092 | A2 | 19860106 | JP 1985-111312 | 19850523 |
| PRIORITY APPLN. INFO.: | | | US 1984-612979 | 19840523 |
| | | | EP 1985-303564 | 19850521 |

AB Simultaneous multiple assays for org. species (e.g., steroids, proteins, **peptides**, carbohydrates, drugs) are described. This procedure makes use of coordinated compds., which are prepd. by labeling an individual org. species with a **radioisotope** through a **chelating** agent of general structure (HO2CCH2)2NCHR[CH2N(CH2CO2H)CH2]nCH2N(CH2CO2H)2 where R = Ph, or Ph substituted with NO2, NH2, and/or SO3H and n = o or 1. **Radiolabeled** org. species cong. individually distinguishable **radionuclides** are combined in a variety of configurations to measure more org. species simultaneously using radioassay. For example, for simultaneous detn. of LH and FSH, 57Co-labeled LH was prepd. by mixing lyophilized LH with diethylenetriaminepentacetic anhydride (I) in Na2CO3 soln. The resulting LH-I was mixed with 57CoCl2 in HCl to yield 57Co-labeled LH. 125I-labeled FSH was prepd. by mixing FSH antigen with Na125I in phosphate-buffered saline. A test sample or std. was mixed with antiserum and incubated for 1 h at 37.degree.. Tracer solns. were added and the reaction mixt. was further incubated for 1 h at room temp. After addn. of pptg. soln., the mixt. was incubated for 10 min at room temp. and centrifuged. The liq. was discarded and the tubes were counted for 125I and 57Co in a .gamma.-counter. Unknown samples were read from a std. curve.

L6 ANSWER 63 OF 68 USPATFULL
ACCESSION NUMBER: 85:68137 USPATFULL
TITLE: Magnetic particles for use in separations
INVENTOR(S): Whitehead, Roy A., Hingham, MA, United States
Chagnon, Mark S., Lowell, MA, United States
Groman, Ernest V., Brookline, MA, United States
Josephson, Lee, Arlington, MA, United States
PATENT ASSIGNEE(S): Advanced Magnetics Inc., Cambridge, MA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 4554088 | | 19851119 |
| APPLICATION INFO.: | US 1983-493991 | | 19830512 (6) |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Demers, Arthur P. | | |
| LEGAL REPRESENTATIVE: | Pennie & Edmonds | | |
| NUMBER OF CLAIMS: | 11 | | |
| EXEMPLARY CLAIM: | 1 | | |
| NUMBER OF DRAWINGS: | 2 Drawing Figure(s); 2 Drawing Page(s) | | |
| LINE COUNT: | 1501 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process is provided for the preparation of magnetic particles to which a wide variety of molecules may be coupled. The magnetic particles can be dispersed in aqueous media without rapid settling and conveniently reclaimed from media with a magnetic field. Preferred particles do not become magnetic after application of a magnetic field and can be redispersed and reused. The magnetic particles are useful in biological systems involving separations.

L6 ANSWER 64 OF 68 USPATFULL
ACCESSION NUMBER: 84:25942 USPATFULL
TITLE: Detecting intrinsic factor blocking site antibody
INVENTOR(S): Ellis, James E., Stoughton, MA, United States
Lidgard, Graham P., Wellesley, MA, United States
Odstrchel, Gerald, Walpole, MA, United States
Riceberg, Louis J., Needham, MA, United States
PATENT ASSIGNEE(S): Corning Glass Works, Corning, NY, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 4447528 | | 19840508 |
| APPLICATION INFO.: | US 1981-291354 | | 19810810 (6) |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Marantz, Sidney | | |
| LEGAL REPRESENTATIVE: | Maycock, W. E. | | |
| NUMBER OF CLAIMS: | 7 | | |
| EXEMPLARY CLAIM: | 1 | | |
| LINE COUNT: | 395 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A radioassay procedure and reagent kit therefor for detecting auto blocking antibody, such as auto blocking antibody which interferes with the complexation of intrinsic factor with vitamin B.sub.12. A receptor, i.e., intrinsic factor, is immobilized on a support and the amount of **ligand**, i.e., vitamin B.sub.12, capable of binding therewith in the presence of a biological fluid sample is determined.

L6 ANSWER 65 OF 68 USPATFULL
ACCESSION NUMBER: 81:30332 USPATFULL
TITLE: Method and composition for double receptor, specific binding assays
INVENTOR(S): Bunting, James R., Washington, DC, United States
PATENT ASSIGNEE(S): Baxter Travenol Laboratories, Inc., Deerfield, IL, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 4271140 | | 19810602 |
| APPLICATION INFO.: | US 1978-930130 | | 19780801 (5) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 1978-871478, filed on 23 Jan 1978, now abandoned | | |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Padgett, Benjamin R. | | |
| ASSISTANT EXAMINER: | Nucker, Christine M. | | |
| LEGAL REPRESENTATIVE: | Flattery, Paul C., Flynn, Lawrence W., Hensley, Max D. | | |
| NUMBER OF CLAIMS: | 45 | | |
| EXEMPLARY CLAIM: | 1 | | |
| LINE COUNT: | 1050 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The performance of double receptor, specific binding assays is improved by use of a receptor complex having the structure

A.sub.BL (BL).sub.n A.sub.1

wherein BL is a binding **ligand**, A.sub.BL is a receptor specific for binding **ligand**, A.sub.1 is a receptor, BL is covalently bonded to A.sub.1 and A.sub.BL is reversibly bonded to BL. Generally A.sub.BL is absorbed onto an insoluble surface and A.sub.1 is an antibody to the substance being assayed. The complex has particular utility in coated tube and rechargeable radioimmunoassay systems.

L6 ANSWER 66 OF 68 USPATFULL
ACCESSION NUMBER: 81:27515 USPATFULL
TITLE: Automated direct serum radioassay
INVENTOR(S): Reese, Max, Salt Lake City, UT, United States
PATENT ASSIGNEE(S): Becton Dickinson & Company, Paramus, NJ, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 4268494 | | 19810519 |
| APPLICATION INFO.: | US 1978-920801 | | 19780630 (5) |
| DISCLAIMER DATE: | 19950822 | | |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 1977-774390, filed on 4 Mar 1977, now patented, Pat. No. US 4108976 | | |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Schafer, Richard E. | | |
| ASSISTANT EXAMINER: | Nucker, Christine M. | | |
| LEGAL REPRESENTATIVE: | Marn, Louis E., Olstein, Elliot M. | | |
| NUMBER OF CLAIMS: | 7 | | |
| EXEMPLARY CLAIM: | 1 | | |
| LINE COUNT: | 499 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Automated radioassay in which a serum is diluted and pre-incubated in the presence of a **radioactive** labeled **ligand**, such as an antigen, and a binder, such as an antibody, specific to the **ligand**. The pre-incubated mixture is flowed through a chamber containing binder specific to the **ligand** supported on a solid support, and the labeled and unlabeled **ligand** not bound to the binder in pre-incubation are bound to the receptor on flow through the chamber. An eluting solution is flowed through the chamber to release the **ligand** bound to the binder in the chamber for reuse thereof. By counting the **radioactivity** of one or both of the fraction which flows through the chamber or which is subsequently released therefrom the quantity of a specific **ligand** in the serum may be assayed.

L6 ANSWER 67 OF 68 USPATFULL

| | |
|---|---|
| ACCESSION NUMBER: | 78:52922 USPATFULL |
| TITLE: | In vitro diagnostic test |
| INVENTOR(S): | Ithakissios, Dionyssis S., St. Paul, MN, United States |
| PATENT ASSIGNEE(S): | Minnesota Mining and Manufacturing Company, St. Paul, MN, United States (U.S. corporation) |

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 4115534 | | 19780919 |
| APPLICATION INFO.: | US 1977-808339 | | 19770620 (5) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 1976-715933, filed on 19 Aug 1976, now abandoned | | |

| | |
|---|---|
| DOCUMENT TYPE: | Utility |
| FILE SEGMENT: | Granted |
| PRIMARY EXAMINER: | Padgett, Benjamin R. |
| ASSISTANT EXAMINER: | Nucker, Christine M. |
| LEGAL REPRESENTATIVE: | Alexander, C., Sell, Donald M., Lilly, James V. |
| NUMBER OF CLAIMS: | 25 |
| EXEMPLARY CLAIM: | 1 |
| NUMBER OF DRAWINGS: | 2 Drawing Figure(s); 1 Drawing Page(s) |
| LINE COUNT: | 804 |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for determining the concentration of substances in biological fluids (e.g., drugs, hormones, vitamins and enzymes) is disclosed wherein magnetically responsive, permeable, solid, water-insoluble microparticles are employed.

L6 ANSWER 68 OF 68 CAPLUS COPYRIGHT 2001 ACS

| | |
|---|---|
| ACCESSION NUMBER: | 1978:34141 CAPLUS |
| DOCUMENT NUMBER: | 88:34141 |
| TITLE: | Detection of genetic variation with **radioactive ligands**. I. Electrophoretic screening of plasma proteins with a selected panel of compounds |
| AUTHOR(S): | Cavalli-Sforza, Luigi L.; Daiger, Stephen P.; Rummel, Diane P. |
| CORPORATE SOURCE: | Dep. Genet., Stanford Univ. Med. Cent., Stanford, Calif., USA |
| SOURCE: | Am. J. Hum. Genet. (1977), 29(6), 581-92 CODEN: AJHGAG |
| DOCUMENT TYPE: | Journal |
| LANGUAGE: | English |

AB To detect new genetic variation in human plasma proteins, a panel of 63 **radioactive** substances were screened as potential radioligands using polyacrylamide gel electrophoresis and autoradiog. Vitamins, hormones, drugs, **amino acids**, purines, pyrimidines, sugars, and lipids labeled with 14C or other **radionuclides** were among those substances tested. A majority bound to albumin and a smaller fraction to prealbumins and lipoproteins. Several vitamins and hormones bound to specific .alpha. and .beta. globulins. Electrophoretic polymorphisms of the vitamin D-binding protein (group-specific component), a vitamin B12-binding protein (transcobalamin II), and thyroxine-binding .alpha.-globulin were obsd. Testosterone-binding .beta.-globulin showed an electrophoretic polymorphism in Caucasians and a possible deficiency allele. Trancortin showed an electrophoretic doublet in all persons tested but no electrophoretic variation. A protein binding a deriv. of norepinephrine or epinephrine was identified as transferrin. A nonpolymorphic protein running cathodal to albumin and binding a deriv. of riboflavin was tentatively identified as a fraction of albumin with mobility altered as a result of interaction with the **ligand**.